```
=> d his

     (FILE 'HOME' ENTERED AT 11:10:49 ON 15 SEP 2008)

     FILE 'REGISTRY' ENTERED AT 11:10:58 ON 15 SEP 2008
L1             STRUCTURE UPLOADED
L2               5 S L1
L3          208241 S 6-7/SZ
L4              50 S L1  SUB=L3 SAM
L5             STRUCTURE UPLOADED
L6               2 S L5
L7              26 S L5  SUB=L3 SAM
L8             444 S L5  SUB=L3 FUL
L9             441 S L8 AND CAPLUS/LC
L10              3 S L8 NOT L9

     FILE 'CAPLUS' ENTERED AT 11:13:34 ON 15 SEP 2008
L11             26 S L8
L12             22 S L11 NOT (2008/SO OR 2007/SO OR 2006/SO)

=> d l5
L5 HAS NO ANSWERS
L5             STR
```




```
Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr total
```

L12 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:804087 CAPLUS
DOCUMENT NUMBER: 149:119663
TITLE: EEG-based determination of histamine 3 (H3) receptor bioactivity
INVENTOR(S): Radek, Richard J.; Bitner, R. Scott; Cowart, Marlon D.; Brioni, Jorge D.; Esbenshade, Timothy A.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S. Pat. Appl. Publ., 15pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20080159958	A1	20080703	US 2007-950560		20071205
PRIORITY APPLN. INFO.:			US 2006-877275P	P	20061227

AB The invention discloses an in vivo method for determining the bioactivity of chemical compds. as histamine 3 receptor (H3R) ligands, and provides animal models to determine such bioactivity. The invention further discloses methods for screening therapeutic compds. demonstrating a desired property, using such methods and models described. Preparation of H3R antagonist (3aR, 6aR)-2-[4'-(5-methylhexahydropyrrolo[3,4-b]pyrrol-1-yl)biphenyl-4-yl]-2H-pyridazin-3-one is described.

IT 720690-73-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(GSK 189254A; EEG-based determination of histamine 3 (H3) receptor bioactivity)

RN 720690-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



L12 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:208237 CAPLUS
DOCUMENT NUMBER: 148:246365
TITLE: Polymorphic form of 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1h-benzoo[d]azepin-7-yloxy)-n-methyl-nicotinamide hydrochloride for use in therapy
INVENTOR(S): Borrett, Gary Thomas; Wilson, David Matthew; Bailey, Nicholas; Steadman, Jon Graham
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: Brit. UK Pat. Appl., 20pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2441014	A	20080220	GB 2006-18135	20060914

PRIORITY APPLN. INFO.: GB 2006-18135 20060914

AB A polymorphic form of 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-N-methyl-nicotinamide hydrochloride (I) is characterized by one or both of the following: an X-ray powder diffraction spectrum comprising peaks at 5% or greater relative intensity of 2 T box = 4.6 and 9.2 (corresponding to lattice spacings of 19.2 angstrom and 9.6 angstrom, resp.) an onset of melting in the range 233-240°C, as measured by DSC. The polymorph may be prepared by treating a solution of the free base, 6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-N-methyl-nicotinamide, in methanol with one equivalent of a chloride source (such as acetyl chloride or HCl), followed by crystallization with at least 1.5 vols. of Et acetate. The polymorph may be used in medicine to treat neurol., psychiatric, sleep and gastrointestinal disorders, pain, epilepsy and obesity. Preparation of I according to above method is disclosed, yield=77%.

IT 720690-73-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(polymorphic form of cyclobutylbenzodiazepin nicotinamide hydrochloride derivative for the treatment of neurol. diseases)
RN 720690-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



IT 945493-87-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(polymorphic form of cyclobutylbenzodiazepin nicotinamide hydrochloride derivative for the treatment of neurol. diseases)
RN 945493-87-8 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1447634 CAPLUS
DOCUMENT NUMBER: 148:54912
TITLE: Preparation of aryl and heteroaryl tetrahydrobenzazepine derivatives as 5-HT agonists useful for treating glaucoma
INVENTOR(S): Mohapatra, Suchismita; Hellberg, Mark R.; Feng, Zixia
PATENT ASSIGNEE(S): Alcon Manufacturing Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 13pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070293475	A1	20071220	US 2007-761493	20070612
WO 2007149728	A2	20071227	WO 2007-US70931	20070612
WO 2007149728	A3	20080703		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-814971P P 20060620
OTHER SOURCE(S): MARPAT 148:54912
GI



I



II

AB Aryl tetrahydrobenzazepine derivs. of general formula I (wherein R1 = H or C1-4 alkyl; R2= H, OH, or alkoxy; R3 = -X-Ar, -OR8, etc.; R4, R5, R6, R7= H or C1-2 alkyl; R8 = H or C1-4 alkyl; X=O, -C(R9)(R10)-, etc.; Ar= (un)substituted Ph or pyridyl; R9, R10 = H or C1-4 alkyl) with minimal 5-HT2B activity relative to 5-HT2A and 5-HT2C activity that are useful for treating glaucoma are disclosed. Example compound II was prepared by reacting 7-chloro-1,2,4,5-tetrahydro-benzo[d]azepine-3-carboxylic acid tert-Bu ester with 3,5-dimethoxybenzyl zinc chloride. In an assay involving functional response of 5-HT2 receptor subtypes, II had EC50 values of 16.9, >10,000, and 20 nm, in activating the 5-HT2A, 5-HT2B, and 5-HT2C receptors, resp.

IT 959867-52-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aryl and heteroaryl tetrahydrobenzazepine derivs. as 5-HT agonists useful for treating glaucoma)

RN 959867-52-8 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[(3-methoxyphenyl)methoxy]-8-methyl-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 959867-51-7
CMF C19 H23 N O2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 959867-55-1P, 7-[(3-Methoxybenzyl)oxy]-8-methyl-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of aryl and heteroaryl tetrahydrobenzazepine derivs. as 5-HT agonists useful for treating glaucoma)

RN 959867-55-1 CAPLUS

CN Ethanone, 2,2,2-trifluoro-1-[1,2,4,5-tetrahydro-7-[(3-methoxyphenyl)methoxy]-8-methyl-3H-3-benzazepin-3-yl]- (CA INDEX NAME)


F3C
C
O
N
Me
O
CH2
OMe

L12 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1176022 CAPLUS
DOCUMENT NUMBER: 147:469249
TITLE: Benzazepinyloxyacetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol and their preparation
INVENTOR(S): Kuo, Gee-Hong; Zhang, Yan; Shen, Lan; Lu, Songfeng; Demarest, Keith T.; Peiton, Patricia
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 113pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070244094	A1	20071018	US 2007-736221	20070417
WO 2007121432	A2	20071025	WO 2007-US66772	20070417

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-793001P P 20060418
OTHER SOURCE(S): MARPAT 147:469249
GI



I



II

AB The invention is directed to compds. of formula I useful as PPAR agonists. Pharmaceutical compns. and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndrome, hypertension, ischemia, stroke, irritable bowel disorder, inflammation, cataract, cardiovascular diseases, Metabolic X Syndrome, hyper-LDL-cholesterolemia, dyslipidemia (including hypertriglyceridemia, hypercholesterolemia, mixed hyperlipidemia, and hypo-HDL-cholesterolemia), atherosclerosis, obesity, and other disorders related to lipid metabolism and energy homeostasis complications thereof, using compds. of the invention are also described. Compds. of formula I wherein X is a covalent bond, O and S; R1 and R2 are independently H, and (un)substituted C1-8 alkyl; R1R2 and the carbon they are attached together may form C3-7 cycloalkyl; R3 is H; R4 and R5 are independently H, halo, C1-8 alkyl, C3-7 cycloalkyl, etc.; R5 and R7 are independently H, halo, C1-3 (halo)alkyl and C1-3 (halo)alkoxy; n is 1; Q is (un)substituted 5- to 6-membered heteroarom. ring; and their enantiomers, diastereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (detailed procedure given). All the invention compds. were evaluated for their PPAR-δ agonistic activity. From the assay, it was determined that compound II exhibited EC50 value of 34.1 nM against PPARδ.

IT 952709-65-8P 952709-66-9P 952709-67-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of benzazepinyloxyacetic acid derivs. as PPAR-delta agonists useful for increasing HDL-C, lower LDL-C and lower cholesterol)

RN 952709-65-8 CAPLUS
CN Cyclopropanecarboxylic acid, 1-[[2,3,4,5-tetrahydro-3-[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)



RN 952709-66-9 CAPLUS
CN Cyclopropanecarboxylic acid, 1-[[2,3,4,5-tetrahydro-3-[[5-[4-(trifluoromethyl)phenyl]-2-furanyl]methyl]-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)



RN 952709-67-0 CAPLUS

CN Cyclopropanecarboxylic acid, 1-[[2,3,4,5-tetrahydro-3-[[2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)



IT 952710-75-7P 952710-78-0P 952710-79-1P
952710-82-6P 952710-83-7P 952710-84-8P
952710-85-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of benzazepinyloxyacetic acid derivs. as PPAR-delta agonists useful for increasing HDL-C, lower LDL-C and lower cholesterol)

RN 952710-75-7 CAPLUS
CN 2(3H)-Furanone, dihydro-3-[[2,3,4,5-tetrahydro-3-[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)



RN 952710-78-0 CAPLUS
CN Cyclopropanecarboxylic acid, 1-[[2,3,4,5-tetrahydro-3-[[5-[4-(trifluoromethyl)phenyl]-2-thienyl]methyl]-1H-3-benzazepin-7-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 952710-79-1 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[(tetrahydro-2-oxo-3-furanyl)oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 952710-82-6 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[1-(methoxycarbonyl)cyclopropyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 952710-83-7 CAPLUS
CN Cyclopropanecarboxylic acid, 1-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, methyl ester (CA INDEX NAME)



RN 952710-84-8 CAPLUS
CN Cyclopropanecarboxylic acid, 1-[[2,3,4,5-tetrahydro-3-[[5-[4-(trifluoromethyl)phenyl]-2-furanyl]methyl]-1H-3-benzazepin-7-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 952710-85-9 CAPLUS
CN Cyclopropanecarboxylic acid, 1-[[2,3,4,5-tetrahydro-3-[[2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]-1H-3-benzazepin-7-yl]oxy]-, methyl ester (CA INDEX NAME)


F3C
S
N
CH2
N
O
C
OMe
O

L12 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:35810 CAPLUS
DOCUMENT NUMBER: 146:142521
TITLE: Preparation of 2,3,4,5-tetrahydro-1H-3-benzazepines as antithrombotic agents
INVENTOR(S): Priepke, Henning; Dahmann, Georg; Gerlach, Kai; Pfau, Roland; Wienen, Wolfgang; Schuler-Metz, Annette; Handschuh, Sandra; Nar, Herbert
PATENT ASSIGNEE(S): Boehringer Ingelheim International GmbH, Germany; Boehringer Ingelheim Pharma Gmbh & Co. KG
SOURCE: PCT Int. Appl., 185pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007003536	A1	20070111	WO 2006-EP63611	20060628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006265216	A1	20070111	AU 2006-265216	20060628
CA 2613059	A1	20070111	CA 2006-2613059	20060628
EP 1899330	A1	20080319	EP 2006-763910	20060628
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				
NO 2007005186	A	20080214	NO 2007-5186	20071011
IN 2007DN09037	A	20080104	IN 2007-DN9037	20071123
MX 200716253	A	20080307	MX 2007-16253	20071218
CN 101213195	A	20080702	CN 2006-80024267	20080102
KR 2008033318	A	20080416	KR 2008-702478	20080130

PRIORITY APPLN. INFO.: EP 2005-14270 A 20050630
WO 2006-EP63611 W 20060628

OTHER SOURCE(S): MARPAT 146:142521
GI



I II

AB Title compds. I [D = substituted bicyclic ring system with provisos; R3 = H, alkyl; R4, R5 = H, alkyl, alkenyl, etc.; M = substituted thiophene with provisos] and their pharmaceutically acceptable salts and formulations were prepared For example, benzazepine II was prepared from 3-trifluoroacetyl-7-nitro-2,3,4,5-tetrahydro-1H-benzo(d)azepine in 6-steps. Compds. I are claimed useful as antithrombotic agents.

IT 919099-11-9P 919099-12-0P 919099-13-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tetrahydrobenzazepines as antithrombotic agents)

RN 919099-11-9 CAPLUS
CN Ethanone, 2,2,2-trifluoro-1-[1,2,4,5-tetrahydro-7-nitro-8-(phenylmethoxy)-3H-3-benzazepin-3-yl]- (CA INDEX NAME)



RN 919099-12-0 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-nitro-8-(phenylmethoxy)- (CA INDEX NAME)



RN 919099-13-1 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-methyl-7-nitro-8-(phenylmethoxy)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1354331 CAPLUS
DOCUMENT NUMBER: 146:93568
TITLE: MAO-B inhibitors useful for treating obesity
INVENTOR(S): McElroy, John F.; Chorvat, Robert J.; Rajagopalan, Parthasarathi
PATENT ASSIGNEE(S): Jenrin Discovery, USA
SOURCE: PCT Int. Appl., 109pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006138475	A2	20061228	WO 2006-US23337	20060615
WO 2006138475	A3	20071213		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20070078172	A1	20070405	US 2006-424274	20060615
PRIORITY APPLN. INFO.:			US 2005-691323P P	20050616
			US 2006-798467P P	20060508

OTHER SOURCE(S): MARPAT 146:93568

AB The invention provides a method of treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance) in a mammal by administering to the mammal a therapeutically effective amount of a MAO-B inhibitor.

IT 917873-69-9 917873-71-3 917873-72-4
917873-74-6 917873-76-8 917873-78-0
917873-80-4 917873-82-6 917873-84-8
917873-86-0 917873-88-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(MAO-B inhibitors useful for treating obesity)

RN 917873-69-9 CAPLUS
CN Ethanone, 1-[7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]- (CA INDEX NAME)



RN 917873-71-3 CAPLUS
CN Ethanone, 1-[7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2-methoxy- (CA INDEX NAME)



RN 917873-72-4 CAPLUS
CN 3H-3-Benzazepine-3-acetamide, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-α-oxo- (CA INDEX NAME)



RN 917873-74-6 CAPLUS
CN 3H-3-Benzazepine-3-propanamide, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-β-oxo- (CA INDEX NAME)



RN 917873-76-8 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-, methyl ester (CA INDEX NAME)



RN 917873-78-0 CAPLUS
CN 3H-3-Benzazepine-3-carboxaldehyde, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro- (CA INDEX NAME)



RN 917873-80-4 CAPLUS
CN 1H-3-Benzazepine, 7-[(3-fluorophenyl)methoxy]-2,3,4,5-tetrahydro-3-(methylsulfonyl)- (CA INDEX NAME)



RN 917873-82-6 CAPLUS
CN 3H-3-Benzazepine-3-carboxamide, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro- (CA INDEX NAME)



RN 917873-84-8 CAPLUS
CN 3H-3-Benzazepine-3-carboxamide, N-ethyl-7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro- (CA INDEX NAME)



RN 917873-86-0 CAPLUS
CN 3H-3-Benzazepine-3-acetamide, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-

tetrahydro- (CA INDEX NAME)



RN 917873-88-2 CAPLUS
CN 3H-3-Benzazepine-3-acetamide, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-α-methyl- (CA INDEX NAME)



L12 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:678394 CAPLUS
DOCUMENT NUMBER: 145:124480
TITLE: Process for the preparation of 6-(2,3,4,5-tetrahydrahydro-1H-benzo[d]azepin-7-yloxy)nicotinamide derivatives as radio-labelled ligands for the human histamine H3 receptor
INVENTOR(S): Plisson, Christophe
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006072596	A1	20060713	WO 2006-EP112	20060105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2594383	A1	20060713	CA 2006-2594383	20060105
EP 1836171	A1	20070926	EP 2006-700405	20060105
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR				
US 20080166298	A1	20080710	US 2007-813357	20070705
PRIORITY APPLN. INFO.:			GB 2005-283 A	20050107
			GB 2005-592 A	20050112
			WO 2006-EP112 W	20060105

OTHER SOURCE(S): CASREACT 145:124480; MARPAT 145:124480
GI



I

AB Isotopomers of 6-(2,3,4,5-tetrahydrahydro-1H-benzo[d]azepin-7-yloxy)nicotinamide derivs. [I; R1 = a radio-labeled group and X = CO, or R1 = C2-6 alkyl and X = 11C; e.g., (11C-N-methyl)-6-(3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)nicotamide] are prepared which demonstrate a high binding affinity to the human histamine H3 receptor (e.g., pKi = 9.59) and are useful for the labeling and diagnostic imaging (e.g., PET scans) of human histamine H3 receptors.

IT 720690-56-2 720691-59-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(in a process for the preparation of 6-(2,3,4,5-tetrahydrahydro-1H-benzo[d]azepin-7-yloxy)nicotinamide derivs. as radio-labeled ligands for the human histamine H3 receptor)

RN 720690-56-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720691-59-8 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(5-iodo-2-pyridinyl)oxy]- (CA INDEX NAME)



IT 836611-32-6P 897928-06-2P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(process for the preparation of 6-(2,3,4,5-tetrahydrahydro-1H-benzo[d]azepin-7-yloxy)nicotinamide derivs. as radio-labeled ligands for the human histamine H3 receptor)

RN 836611-32-6 CAPLUS
CN 3-Pyridinecarboxamide-11C, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (9CI) (CA INDEX NAME)



RN 897928-06-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(methyl-11C)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1354902 CAPLUS
DOCUMENT NUMBER: 144:69750
TITLE: Preparation of 3-cycloalkylbenzazepine derivatives as histamine H3 antagonists for treatment of neurological disease
INVENTOR(S): Bamford, Mark James; Pickering, Paula Louise; Wilson, David Matthew
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123723	A1	20051229	WO 2005-EP6861	20050616
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1756094	A1	20070228	EP 2005-755373	20050616
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
JP 2008502644	T	20080131	JP 2007-515905	20050616
US 20070232590	A1	20071004	US 2006-570383	20061211

PRIORITY APPLN. INFO.:

GB 2004-13757	A	20040618
GB 2004-13758	A	20040618
GB 2004-13763	A	20040618
GB 2004-13764	A	20040618
GB 2004-13765	A	20040618
GB 2004-13766	A	20040618
GB 2004-13768	A	20040618
GB 2004-13769	A	20040618
GB 2004-13770	A	20040618
WO 2005-EP6861	W	20050616

OTHER SOURCE(S): CASREACT 144:69750; MARPAT 144:69750
GI



I II

AB The title benzazepine derivs. I [wherein R = cycloalkyl; Ar = (un)substituted aryl or heteroaryl] or pharmaceutically acceptable salts thereof were prepared as histamine H3 antagonists for treatment of neurol. disease. For example, the compound II was prepared in a multi-step synthesis in good yield. II showed antagonistic activity with fPKi of 10.1 against histamine H3.

IT 871737-37-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of 3-cycloalkylbenzazepine derivs. as histamine H3 antagonists)

RN 871737-37-0 CAPLUS

CN 2-Pyrrolidinone, 1-[6-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



IT 871737-38-1P 871737-39-2P 871737-40-5P
871737-41-6P 871737-42-7P 871737-43-8P
871737-44-9P 871737-45-0P 871737-46-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of 3-cycloalkylbenzazepine derivs. as histamine H3 antagonists)

RN 871737-38-1 CAPLUS

CN 2-Pyrrolidinone, 1-[5-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]- (CA INDEX NAME)



RN 871737-39-2 CAPLUS

CN 2-Imidazolidinone, 1-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-fluorophenyl]-3-methyl- (CA INDEX NAME)



RN 871737-40-5 CAPLUS
CN 2-Pyrrolidinone, 1-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]phenyl]- (CA INDEX NAME)



RN 871737-41-6 CAPLUS
CN 2-Oxazolidinone, 3-[6-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridazinyl]- (CA INDEX NAME)



RN 871737-42-7 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridazinyl]- (CA INDEX NAME)



RN 871737-43-8 CAPLUS
CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyrazinyl]oxy]- (CA INDEX NAME)



RN 871737-44-9 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 871737-45-0 CAPLUS
CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 871737-46-1 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 720689-52-1P 720692-27-3P 720692-43-3P
720692-44-4P 720692-55-7P 720692-56-8P
720692-95-5P 720692-96-6P 720692-97-7P
720692-98-8P 866939-13-1P 866939-14-2P
866939-15-3P 866939-27-7P 866939-28-8P
866939-29-9P 866939-37-9P 866939-38-0P
866939-39-1P 866939-40-4P 871737-47-2P
871737-48-3P 871737-49-4P 871737-50-7P

871737-51-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 3-cycloalkylbenzazepine derivs. as histamine H3 antagonists)

RN 720689-52-1 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(phenylmethoxy)- (CA INDEX NAME)



RN 720692-27-3 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-7-(2-fluoro-4-iodophenoxy)-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720692-43-3 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-(phenylmethoxy)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-44-4 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-(phenylmethoxy)- (CA INDEX NAME)



RN 720692-55-7 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[5-(methoxycarbonyl)-2-pyrazinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-56-8 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5-carboxy-2-pyrazinyl)oxy]-1,2,4,5-tetrahydro-, 3-(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 720692-95-5 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-(2-fluoro-4-nitrophenoxy)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-96-6 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-(4-amino-2-fluorophenoxy)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-97-7 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-(2-fluoro-4-iodophenoxy)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-98-8 CAPLUS
CN 1H-3-Benzazepine, 7-(2-fluoro-4-iodophenoxy)-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 866939-13-1 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5-chloro-2-pyrazinyl)oxy]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-14-2 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[5-(2-oxo-1-pyrrolidinyl)-2-pyrazinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-15-3 CAPLUS
CN 2-Pyrrolidinone, 1-[5-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]- (CA INDEX NAME)



RN 866939-27-7 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5-bromo-2-pyridinyl)oxy]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-28-8 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[5-(2-oxo-1-pyrrolidinyl)-2-pyridinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-29-9 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 866939-37-9 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[5-(methoxycarbonyl)-2-pyridinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-38-0 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5-carboxy-2-pyridinyl)oxy]-1,2,4,5-tetrahydro-, 3-(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 866939-39-1 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-40-4 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 871737-47-2 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[(5-iodo-2-pyridinyl)oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 871737-48-3 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(4-iodophenoxy)- (CA INDEX NAME)



RN 871737-49-4 CAPLUS
CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-[(6-iodo-3-pyridazinyl)oxy]- (CA INDEX NAME)



RN 871737-50-7 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyrazinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 871737-51-8 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyrazinyl]oxy]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1126686 CAPLUS
DOCUMENT NUMBER: 143:386938
TITLE: Preparation of tertrahydrobenzazepines as histamine H3 and H1 receptor ligands
INVENTOR(S): Heightman, Thomas Daniel; Wilson, David Matthew
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097778	A1	20051020	WO 2005-GB1333	20050406
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1735299	A1	20061227	EP 2005-732871	20050406
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
JP 2007532523	T	20071115	JP 2007-506834	20050406
US 20080009479	A1	20080110	US 2006-599636	20061004
PRIORITY APPLN. INFO.:			GB 2004-8083 A	20040408
			WO 2005-GB1333 W	20050406

OTHER SOURCE(S): CASREACT 143:386938; MARPAT 143:386938
GI



I



II



III

AB Title compds. I [wherein R1 = (un)substituted alkyl; R2 = (un)substituted alkyl, aryl, etc.; R3 = halo, alkyl, alkoxy, cyano, amino or CF3; n = 0-2, or pharmaceutically acceptable salts thereof] were prepared as ligands of histamine receptors, especially histamine H3 receptors. For instance, 2,5-dichloropyrazine, which was obtained from aminopyrazine in two steps, underwent successive substitution with phenol II and 2-pyrrolidinone followed by deprotection with TFA. The resultant amine was reductively alkylated with cyclopropanecarboxaldehyde in the presence of sodium triacetoxyborohydride and catalytic amount of HOAc to give III. This compound exhibited antagonism >9 pKb and < 6.5 pKb in the histamine H3 and H1 functional antagonist assays, resp. Therefore, I and their pharmaceutical compns. are useful in the treatment of neurol. and psychiatric disorders (no data).

IT 866939-19-7P, 3-(Cyclopropylmethyl)-7-[(4-piperidinylmethyl)oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine 866939-21-1P, 1,1-Dimethylethyl 4-[[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]methyl]-1-piperidinecarboxylate 866939-42-6P, 3-(Cyclopropylmethyl)-7-[(4-iodophenyl)oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine 866939-51-7P, 1,1-Dimethylethyl 4-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-1-piperidinecarboxylate 866939-52-8P, 3-(Cyclopropylmethyl)-7-(4-piperidinyloxy)-2,3,4,5-tetrahydro-1H-3-benzazepine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(ligand; preparation of tertrahydrobenzazepines as histamine H1 and H3 receptor ligands)

RN 866939-19-7 CAPLUS

CN 1H-3-Benzazepine, 3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-7-(4-piperidinylmethoxy)- (CA INDEX NAME)



RN 866939-21-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-42-6 CAPLUS
CN 1H-3-Benzazepine, 3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-7-(4-iodophenoxy)- (CA INDEX NAME)



RN 866939-51-7 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-52-8 CAPLUS
CN 1H-3-Benzazepine, 3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-7-(4-piperidinyloxy)- (CA INDEX NAME)



IT 866939-12-0P 866939-16-4P, 3-(1-Methylethyl)-7-[(phenylmethyl)oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine 866939-17-5P, 3-(2-Methylpropyl)-7-[(phenylmethyl)oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine 866939-18-6P, 3-Ethyl-7-[(phenylmethyl)oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine 866939-22-2P, 4-[[4-[[[3-(Cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]methyl]-1-piperidinyl]carbonyl]benzonitrile 866939-23-3P, 3-(Cyclopropylmethyl)-7-[[[1-[(4-fluorophenyl)carbonyl]-4-piperidinyl]methyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine 866939-24-4P, 7-[[[1-(Cyclopropylcarbonyl)-4-piperidinyl]methyl]oxy]-3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine 866939-25-5P, 3-(Cyclopropylmethyl)-7-[[[1-[(tetrahydro-2H-pyran-4-yl)carbonyl]-4-piperidinyl]methyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine 866939-26-6P, 1-[6-[[3-(1-Methylethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-3-pyridinyl]-2-pyrrolidinone 866939-30-2P, 1-[6-[[3-(2-Methylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-3-pyridinyl]-2-pyrrolidinone

866939-31-3P, 1-[6-[[3-(2,2-Dimethylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-3-pyridinyl]-2-pyrrolidinone 866939-32-4P, 1-[6-[[3-(Cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-3-pyridinyl]-2-pyrrolidinone 866939-33-5P, 1-[6-[(3-Ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-2-pyrrolidinone 866939-34-6P, 1-[6-[[3-(1-Methylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-3-pyridinyl]-2-pyrrolidinone 866939-35-7P, 1-[6-[[3-(Cyclobutylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-3-pyridinyl]-2-pyrrolidinone 866939-36-8P, 3-(Cyclopropylmethyl)-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine 866939-41-5P, 1-[4-[[3-(Cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]phenyl]-3-methyl-2-imidazolidinone 866939-43-7P, 3-(Cyclopropylmethyl)-7-[(phenylmethyl)oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine 866939-45-9P, 3-(Cyclopropylmethyl)-7-(phenyloxy)-2,3,4,5-tetrahydro-1H-3-benzazepine 866939-48-2P, Ethyl 4-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]benzoate 866939-49-3P, 6-[[3-(Cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-N-methyl-3-pyridinecarboxamide 866939-50-6P, 5-[[3-(Cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-N-methyl-2-pyrazinecarboxamide 866939-53-9P, 4-[[4-[[3-(Cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-1-piperidinyl]carbonyl]benzonitrile 866939-54-0P, 1-[5-[[3-(Cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-2-pyridinyl]-2-pyrrolidinone 866939-58-4P, 1-[5-[[3-(2-Methylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-2-pyridinyl]-2-pyrrolidinone 866939-59-5P, 1-[5-[[3-(1-Methylethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-2-pyridinyl]-2-pyrrolidinone
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(ligand; preparation of tertrahydrobenzazepines as histamine H1 and H3 receptor ligands)

RN 866939-12-0 CAPLUS
CN 2-Pyrrolidinone, 1-[5-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-2-pyrazinyl]- (CA INDEX NAME)



RN 866939-16-4 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(1-methylethyl)-7-(phenylmethoxy)- (CA INDEX NAME)



RN 866939-17-5 CAPLUS

CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-3-(2-methylpropyl)-7-(phenylmethoxy)- (CA INDEX NAME)



RN 866939-18-6 CAPLUS
CN 1H-3-Benzazepine, 3-ethyl-2,3,4,5-tetrahydro-7-(phenylmethoxy)- (CA INDEX NAME)



RN 866939-22-2 CAPLUS
CN Benzonitrile, 4-[[4-[[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]methyl]-1-piperidinyl]carbonyl]- (CA INDEX NAME)



RN 866939-23-3 CAPLUS
CN Methanone, [4-[[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]methyl]-1-piperidinyl](4-fluorophenyl)- (CA INDEX NAME)



RN 866939-24-4 CAPLUS
CN Methanone, cyclopropyl[4-[[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]methyl]-1-piperidinyl]- (CA INDEX NAME)



RN 866939-25-5 CAPLUS
CN Methanone, [4-[[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]methyl]-1-piperidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 866939-26-6 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[[2,3,4,5-tetrahydro-3-(1-methylethyl)-1H-3-benzazepin-7-yl]oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 866939-30-2 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[[2,3,4,5-tetrahydro-3-(2-methylpropyl)-1H-3-benzazepin-7-yl]oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 866939-31-3 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[[3-(2,2-dimethylpropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 866939-32-4 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 866939-33-5 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[(3-ethyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 866939-34-6 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[[2,3,4,5-tetrahydro-3-(1-methylpropyl)-1H-3-benzazepin-7-yl]oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 866939-35-7 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[[3-(cyclobutylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 866939-36-8 CAPLUS
CN 1H-3-Benzazepine, 3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 866939-41-5 CAPLUS
CN 2-Imidazolidinone, 1-[4-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]phenyl]-3-methyl- (CA INDEX NAME)



RN 866939-43-7 CAPLUS
CN 1H-3-Benzazepine, 3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-7-(phenylmethoxy)- (CA INDEX NAME)



RN 866939-45-9 CAPLUS
CN 1H-3-Benzazepine, 3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-7-phenoxy- (CA INDEX NAME)



RN 866939-48-2 CAPLUS
CN Benzoic acid, 4-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-, ethyl ester (CA INDEX NAME)



RN 866939-49-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 866939-50-6 CAPLUS
CN 2-Pyrazinecarboxamide, 5-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-N-methyl- (CA INDEX NAME)



RN 866939-53-9 CAPLUS
CN Benzonitrile, 4-[[4-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-1-piperidinyl]carbonyl]- (CA INDEX NAME)



RN 866939-54-0 CAPLUS
CN 2-Pyrrolidinone, 1-[5-[[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-2-pyridinyl]- (CA INDEX NAME)



RN 866939-58-4 CAPLUS
CN 2-Pyrrolidinone, 1-[5-[[2,3,4,5-tetrahydro-3-(2-methylpropyl)-1H-3-benzazepin-7-yl]oxy]-2-pyridinyl]- (CA INDEX NAME)



RN 866939-59-5 CAPLUS
CN 2-Pyrrolidinone, 1-[5-[[2,3,4,5-tetrahydro-3-(1-methylethyl)-1H-3-benzazepin-7-yl]oxy]-2-pyridinyl]- (CA INDEX NAME)



IT 720692-43-3P, 1,1-Dimethylethyl 7-[(phenylmethyl)oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 720692-44-4P, 7-[(Phenylmethyl)oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine 720692-48-8P, 1,1-Dimethylethyl 7-[[5-[(methylamino)carbonyl]-2-pyridinyl]oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 720692-49-9P, N-Methyl-6-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinecarboxamide 720692-54-6P, N-Methyl-5-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinecarboxamide 720692-55-7P, 1,1-Dimethylethyl 7-[[5-[(methyloxy)carbonyl]-2-pyrazinyl]oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 720692-56-8P, 5-[[3-[[(1,1-Dimethylethyl)oxy]carbonyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-2-pyrazinecarboxylic acid 720692-57-9P, 1,1-Dimethylethyl 7-[[5-[(methylamino)carbonyl]-2-pyrazinyl]oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 866939-13-1P, 1,1-Dimethylethyl 7-[(5-chloro-2-pyrazinyl)oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 866939-14-2P, 1,1-Dimethylethyl 7-[[5-(2-oxo-1-pyrrolidinyl)-2-pyrazinyl]oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 866939-15-3P, 1-[5-[(2,3,4,5-Tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]-2-pyrrolidinone 866939-27-7P, 1,1-Dimethylethyl 7-[(5-bromo-2-pyridinyl)oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 866939-28-8P, 1,1-Dimethylethyl 7-[[5-(2-oxo-1-pyrrolidinyl)-2-pyridinyl]oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 866939-29-9P, 1-[6-[(2,3,4,5-Tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-2-pyrrolidinone 866939-37-9P, 1,1-Dimethylethyl 7-[[5-[(methyloxy)carbonyl]-2-pyridinyl]oxy]-1,2,4,5-

tetrahydro-3H-3-benzazepine-3-carboxylate 866939-38-0P, 6-[[3-[[(1,1-Dimethylethyl)oxy]carbonyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]-3-pyridinecarboxylic acid 866939-39-1P, 1,1-Dimethylethyl 7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 866939-40-4P, 7-[[5-(3-Methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine 866939-46-0P, 1,1-Dimethylethyl 7-(phenyloxy)-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 866939-47-1P, 7-(Phenyloxy)-2,3,4,5-tetrahydro-1H-3-benzazepine 866939-55-1P, 1,1-Dimethylethyl 7-[(6-chloro-3-pyridinyl)oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 866939-56-2P, 1,1-Dimethylethyl 7-[[6-(2-oxo-1-pyrrolidinyl)-3-pyridinyl]oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 866939-57-3P, 1-[5-[(2,3,4,5-Tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]-2-pyrrolidinone
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tertrahydrobenzazepines as histamine H1 and H3 receptor ligands)

RN 720692-43-3 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-(phenylmethoxy)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-44-4 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-(phenylmethoxy)- (CA INDEX NAME)



RN 720692-48-8 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[5-[(methylamino)carbonyl]-2-pyridinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-49-9 CAPLUS

CN 3-Pyridinecarboxamide, N-methyl-6-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-54-6 CAPLUS
CN 2-Pyrazinecarboxamide, N-methyl-5-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-55-7 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[5-(methoxycarbonyl)-2-pyrazinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-56-8 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5-carboxy-2-pyrazinyl)oxy]-1,2,4,5-tetrahydro-, 3-(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 720692-57-9 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[5-[(methylamino)carbonyl]-2-pyrazinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-13-1 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5-chloro-2-pyrazinyl)oxy]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-14-2 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[5-(2-oxo-1-pyrrolidinyl)-2-pyrazinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-15-3 CAPLUS
CN 2-Pyrrolidinone, 1-[5-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]- (CA INDEX NAME)



RN 866939-27-7 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5-bromo-2-pyridinyl)oxy]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-28-8 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[5-(2-oxo-1-pyrrolidinyl)-2-pyridinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-29-9 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 866939-37-9 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[5-(methoxycarbonyl)-2-pyridinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-38-0 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5-carboxy-2-pyridinyl)oxy]-1,2,4,5-tetrahydro-, 3-(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 866939-39-1 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-40-4 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 866939-46-0 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-phenoxy-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-47-1 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-phenoxy- (CA INDEX NAME)



RN 866939-55-1 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(6-chloro-3-pyridinyl)oxy]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-56-2 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[6-(2-oxo-1-pyrrolidinyl)-3-pyridinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 866939-57-3 CAPLUS
CN 2-Pyrrolidinone, 1-[5-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1050865 CAPLUS
DOCUMENT NUMBER: 143:347172
TITLE: Preparation of imidazoles as inhibitors of glutaminyl cyclase.
INVENTOR(S): Schilling, Stephan; Buchholz, Mirko; Niestroj, Andre Johannes; Heiser, Ulrich; Demuth, Hans-Ulrich
PATENT ASSIGNEE(S): Probiodrug Ag, Germany
SOURCE: U.S. Pat. Appl. Publ., 53 pp., Cont.-in-part of U.S. Ser. No. 838,993.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20050215573	A1	20050929	US 2005-51760		20050204
US 7304086	B2	20071204			
US 20040224875	A1	20041111	US 2004-838993		20040505
US 7371871	B2	20080513			
PRIORITY APPLN. INFO.:			US 2004-542133P	P	20040205
			US 2004-838993	A2	20040505
			US 2004-634364P	P	20041208
			US 2003-468014P	P	20030505

OTHER SOURCE(S): CASREACT 143:347172; MARPAT 143:347172
GI



I

AB Title compds. [I; A = (Ph-, cycloalkyl-interrupted) alkylene, alkenylene, alkynylene; B = NHC(:X)NHD, C(:X)NHD, C(:X)SD, etc.; D = alkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl, heterocyclyl, etc.; X = O, S, imino, (substituted) CH2], with specific exceptions, were prepared Thus, 3,4-methylenedioxyphenyl isothiocyanate and 3-(1H-imidazol-1-yl)propylamine were refluxed together for 2 h in EtOH to give 51.3% 1-[3-(1H-imidazol-1-yl)propyl]-3-(3,4-dimethoxyphenyl)thiourea. The latter showed an IC50 = 0.22 μM for inhibition of glutaminyl cyclase. Peptide inhibitors of dipeptidyl peptidase IV were also prepared
IT 720690-73-3, GSK 189254A
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of imidazoles as inhibitors of glutaminyl cyclase)
RN 720690-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:823672 CAPLUS
DOCUMENT NUMBER: 143:229851
TITLE: Preparation of imidazolyl thiourea derivatives as inhibitors of glutaminyl cyclase
INVENTOR(S): Schilling, Stephan; Buchholz, Mirko; Niestroj, Andre Johannes; Demuth, Hans-Ulrich; Heiser, Ulrich
PATENT ASSIGNEE(S): Probiodrug A.-G., Germany
SOURCE: PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005075436	A2	20050818	WO 2005-EP1153		20050204
WO 2005075436	A3	20051208			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
US 20040224875	A1	20041111	US 2004-838993		20040505
US 7371871	B2	20080513			
AU 2005210004	A1	20050818	AU 2005-210004		20050204
CA 2554809	A1	20050818	CA 2005-2554809		20050204
EP 1713780	A2	20061025	EP 2005-707206		20050204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
CN 1918131	A	20070221	CN 2005-80004289		20050204
BR 2005007485	A	20070710	BR 2005-7485		20050204
JP 2007520520	T	20070726	JP 2006-551809		20050204
IN 2006KN02139	A	20070518	IN 2006-KN2139		20060728
MX 2006PA08868	A	20061030	MX 2006-PA8868		20060804
PRIORITY APPLN. INFO.:			US 2004-542133P	P	20040205
			US 2004-838993	A	20040505
			US 2004-634364P	P	20041208
			US 2003-468014P	P	20030505
			WO 2005-EP1153	W	20050204

OTHER SOURCE(S): CASREACT 143:229851; MARPAT 143:229851
GI



I



II

AB Title compds. I [A = alkyl, alkenyl, alkynyl, etc.; B = substituted thiourea, urea, amide, etc.] and their pharmaceutical acceptable salts, are prepared and disclosed as glutaminyl cyclase inhibitors. Thus, e.g., II was prepared by coupling of 1H-imidazole-1-propanamine with the corresponding isothiocyanate. The inhibitory activity of I towards DP IV was evaluated using chromogenic enzyme assay and it was revealed that selected compds. of the invention displayed Ki values in the range of 0.06 up to 204.5 μM. I as glutaminyl cyclase inhibitors should prove useful in the treatment of Alzheimer's disease, depression and dementia. Pharmaceutical compns. comprising I are disclosed.

IT 720690-73-3, GSK 189254A
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(claimed co-drugs; preparation of imidazolyl thiourea derivs. as inhibitors of glutaminyl cyclase)

RN 720690-73-3 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



L12 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:547557 CAPLUS
DOCUMENT NUMBER: 143:53543
TITLE: The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist, and therapeutic use thereof
INVENTOR(S): Cremers, Thomas Ivo Franciscus Hubert; Hogg Willigers, Sandra
PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005056056	A2	20050623	WO 2004-DK862	20041214
WO 2005056056	A3	20060202		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004296531	A1	20050623	AU 2004-296531	20041214
CA 2549574	A1	20050623	CA 2004-2549574	20041214
EP 1696896	A2	20060906	EP 2004-803015	20041214
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
BR 2004015899	A	20070109	BR 2004-15899	20041214
CN 1893935	A	20070110	CN 2004-80037386	20041214
JP 2007513896	T	20070531	JP 2006-543369	20041214
MX 2006PA05127	A	20060711	MX 2006-PA5127	20060508
NO 2006003267	A	20060713	NO 2006-3267	20060713
US 20070066601	A1	20070322	US 2006-596348	20060714
PRIORITY APPLN. INFO.:			DK 2003-1854 A	20031215
			US 2003-529491P P	20031215
			WO 2004-DK862 W	20041214

AB The invention discloses the use of a serotonin reuptake inhibitor and a H3 receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, drug abuse or any other disorder responsive to serotonin reuptake inhibitor.
IT 720690-73-3, GSK 189254A
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(combination of serotonin reuptake inhibitor and H3 receptor antagonist, inverse agonist or partial agonist, and therapeutic use)

RN 720690-73-3 CAPLUS

CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



L12 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:395109 CAPLUS
DOCUMENT NUMBER: 142:447129
TITLE: Preparation of benzyloxybenzazepines as monoamine oxidase-B (MAO-B) inhibitors
INVENTOR(S): Jolidon, Synese; Rodriguez Sarmiento, Rosa Maria; Thomas, Andrew William; Wostl, Wolfgang; Wyler, Rene
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005039591	A1	20050506	WO 2004-EP11541	20041014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004283452	A1	20050506	AU 2004-283452	20041014
CA 2543287	A1	20050506	CA 2004-2543287	20041014
EP 1680127	A1	20060719	EP 2004-790400	20041014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
CN 1871013	A	20061129	CN 2004-80030923	20041014
BR 2004015842	A	20070102	BR 2004-15842	20041014
JP 2007509094	T	20070412	JP 2006-536004	20041014
US 20050107360	A1	20050519	US 2004-967567	20041018
US 7173023	B2	20070206		
TW 254707	B	20060511	TW 2004-93131855	20041020
MX 2006PA04307	A	20060605	MX 2006-PA4307	20060418
IN 2006CN01382	A	20070622	IN 2006-CN1382	20060421
KR 856141	B1	20080903	KR 2006-707779	20060421
NO 2006001907	A	20060712	NO 2006-1907	20060428
US 20070117791	A1	20070524	US 2007-652970	20070112

PRIORITY APPLN. INFO.:	EP 2003-24297	A	20031023
	WO 2004-EP11541	W	20041014
	US 2004-967567	A3	20041018

OTHER SOURCE(S): CASREACT 142:447129; MARPAT 142:447129
GI



I

AB Title compds. [I; R1 = H, Me; R2 = H, alkyl, CH2CONH2, CHMeCONH2, SO2Me, COR6; R3-R5 = H, halo, cyano, alkyl, alkoxy; R6 = H, Me, CH2OMe, CONH2, CH2CONH2, OMe, NH2, NHEt; XX1, YY1 = CH2CH2, CH:CH, CH2CO; or XX1 = CH2, YY1 = CH2CH2CO; with provisos], were prepared Thus, Ac2O and HCO2H were stirred 2 h at 60°; the mixture was cooled to room temperature, diluted with THF, and 7-(3-fluorobenzyloxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine in THF/CH2Cl2 was added followed by stirring for 1 h to give 82% 7-(3-fluorobenzyloxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine-3-carboxaldehyde. The latter inhibited human MAO-B with IC50 = 0.007 μM.

IT 917873-69-9P 917873-71-3P 917873-72-4P
917873-74-6P 917873-76-8P 917873-78-0P
917873-80-4P 917873-82-6P 917873-84-8P
917873-86-0P 917873-88-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of benzyloxybenzazepines as monoamine oxidase-B
inhibitors)

RN 917873-69-9 CAPLUS

CN Ethanone, 1-[7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]- (CA INDEX NAME)



RN 917873-71-3 CAPLUS

CN Ethanone, 1-[7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2-methoxy- (CA INDEX NAME)



RN 917873-72-4 CAPLUS
CN 3H-3-Benzazepine-3-acetamide, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-α-oxo- (CA INDEX NAME)



RN 917873-74-6 CAPLUS
CN 3H-3-Benzazepine-3-propanamide, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-β-oxo- (CA INDEX NAME)



RN 917873-76-8 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-, methyl ester (CA INDEX NAME)



RN 917873-78-0 CAPLUS
CN 3H-3-Benzazepine-3-carboxaldehyde, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro- (CA INDEX NAME)



RN 917873-80-4 CAPLUS

CN 1H-3-Benzazepine, 7-[(3-fluorophenyl)methoxy]-2,3,4,5-tetrahydro-3-(methylsulfonyl)- (CA INDEX NAME)



RN 917873-82-6 CAPLUS
CN 3H-3-Benzazepine-3-carboxamide, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro- (CA INDEX NAME)



RN 917873-84-8 CAPLUS
CN 3H-3-Benzazepine-3-carboxamide, N-ethyl-7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro- (CA INDEX NAME)



RN 917873-86-0 CAPLUS
CN 3H-3-Benzazepine-3-acetamide, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro- (CA INDEX NAME)



RN 917873-88-2 CAPLUS
CN 3H-3-Benzazepine-3-acetamide, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-α-methyl- (CA INDEX NAME)



IT 851343-23-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzyloxybenzazepines as monoamine oxidase-B inhibitors)
RN 851343-23-2 CAPLUS
CN 1H-3-Benzazepine, 7-[(3-fluorophenyl)methoxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)



IT 851343-16-3P 851343-17-4P 851343-18-5P
851343-19-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzyloxybenzazepines as monoamine oxidase-B inhibitors)
RN 851343-16-3 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 851343-17-4 CAPLUS
CN 1H-3-Benzazepine, 7-[(3-fluorophenyl)methoxy]-2,3,4,5-tetrahydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 851343-18-5 CAPLUS
CN 3H-3-Benzazepine-3-acetic acid, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-α-oxo-, ethyl ester (CA INDEX NAME)



RN 851343-19-6 CAPLUS
CN 3H-3-Benzazepine-3-propanoic acid, 7-[(3-fluorophenyl)methoxy]-1,2,4,5-tetrahydro-β-oxo-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:140980 CAPLUS
DOCUMENT NUMBER: 142:204628
TITLE: Radiolabeled imaging agents
INVENTOR(S): Bender, Dirk; Aburel, Pompiliu Sorin
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005014479	A2	20050217	WO 2004-EP8830		20040805
WO 2005014479	A3	20060601			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2536659	A1	20050217	CA 2004-2536659		20040805
EP 1663868	A2	20060607	EP 2004-763865		20040805
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR					
JP 2007501764	T	20070201	JP 2006-522964		20040805
US 20070059230	A1	20070315	US 2006-567524		20061012
PRIORITY APPLN. INFO.:			GB 2003-18728	A	20030808
			GB 2004-16141	A	20040719
			WO 2004-EP8830	W	20040805

AB A novel process for preparing radiolabeled compds. by incorporation of radioactive carbonyl groups into precursors, which are then used to make the radiolabeled compds. These radiolabeled compds. have a number of uses including in vivo imaging techniques such as positron emission tomog. [11C]-Borane carbonyl is used as the labeled agent.

IT 836611-32-6P
RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
([11C]-borane carbonyl in preparation of radiopharmaceuticals)

RN 836611-32-6 CAPLUS

CN 3-Pyridinecarboxamide-11C, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (9CI) (CA INDEX NAME)



IT 720691-59-8
RL: RCT (Reactant); RACT (Reactant or reagent)
([11C]-borane carbonyl in preparation of radiopharmaceuticals)
RN 720691-59-8 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(5-iodo-2-pyridinyl)oxy]- (CA INDEX NAME)



L12 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:546416 CAPLUS
DOCUMENT NUMBER: 141:106391
TITLE: Preparation of benzo[d]azepine derivatives as antagonists and/or inverse agonists of the histamine H3 receptor for the treatment of neurological disorders
INVENTOR(S): Bamford, Mark James; Dean, David Kenneth; Sehmi, Sanjeet Singh; Wilson, David Matthew; Witherington, Jason
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 106 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056369	A1	20040708	WO 2003-EP14556	20031218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509413	A1	20040708	CA 2003-2509413	20031218
AU 2003294909	A1	20040714	AU 2003-294909	20031218
AU 2003294909	B2	20070517		
EP 1572215	A1	20050914	EP 2003-785885	20031218
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017483	A	20051116	BR 2003-17483	20031218
CN 1726042	A	20060125	CN 2003-80106364	20031218
JP 2006512412	T	20060413	JP 2005-502553	20031218
NZ 540148	A	20071130	NZ 2003-540148	20031218
ZA 2005004270	A	20060726	ZA 2005-4270	20050525
IN 2005DN02232	A	20070105	IN 2005-DN2232	20050526
US 20060040918	A1	20060223	US 2005-539385	20050616
MX 2005PA06567	A	20050816	MX 2005-PA6567	20050617
KR 765027	B1	20071009	KR 2005-711441	20050617
NO 2005003384	A	20050915	NO 2005-3384	20050712
US 20070299056	A1	20071227	US 2007-831191	20070731
KR 2007089762	A	20070831	KR 2007-719049	20070820

PRIORITY APPLN. INFO.:	GB 2002-29820	A	20021220
	GB 2003-12607	A	20030602
	WO 2003-EP14556	W	20031218
	US 2005-539385	A3	20050616
	KR 2005-711441	A3	20050617

OTHER SOURCE(S): MARPAT 141:106391
GI



I

AB The title compds. [I; R1 = cycloalkyl optionally substituted by alkyl; R2 = H, alkyl, X(cycloalkyl), X(aryl), etc.; X = a bond, alkyl; R3 = halo, alkyl, alkoxy, CN, NH2, CF3; n = 0-2], useful in the treatment of neurol. and psychiatric disorders, were prepared Thus, reacting 7-benzyloxy-1,2,4,5-tetrahydrobenzo[d]azepine (preparation given) with cyclobutanone in the presence of NaBH(OAc)3 afforded I [R1 = cyclobutyl; R2 = CH2Ph; n = 0] which showed pKb of 9.0-10.5 in the histamine H3 functional antagonist assay. The pharmaceutical composition comprising the compound I is claimed.

IT 720689-52-1P 720689-53-2P 720689-57-6P
720689-58-7P 720689-59-8P 720689-60-1P
720689-61-2P 720689-62-3P 720689-63-4P
720689-64-5P 720690-40-4P 720690-41-5P
720690-46-0P 720690-47-1P 720690-74-4P
720691-00-9P 720691-01-0P 720691-02-1P
720691-59-8P 720691-60-1P 720691-63-4P
720691-66-7P 720691-78-1P 720691-83-8P
720691-84-9P 720691-85-0P 720691-86-1P
720691-88-3P 720692-09-1P 720692-11-5P
720692-24-0P 720692-25-1P 720692-27-3P
720693-38-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzo[d]azepine derivs. as antagonists and/or inverse agonists of the histamine H3 receptor for the treatment of neurol. disorders)

RN 720689-52-1 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(phenylmethoxy)- (CA INDEX NAME)



RN 720689-53-2 CAPLUS
CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-(phenylmethoxy)- (CA INDEX NAME)



RN 720689-57-6 CAPLUS
CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-(4-piperidinyloxy)-
(CA INDEX NAME)



RN 720689-58-7 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(4-piperidinyloxy)-
(CA INDEX NAME)



RN 720689-59-8 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(4-piperidinylmethoxy)-
(CA INDEX NAME)



RN 720689-60-1 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(2R)-2-
pyrrolidinylmethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720689-61-2 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(3R)-3-pyrrolidinyloxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720689-62-3 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(3S)-3-pyrrolidinyloxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720689-63-4 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(2S)-2-pyrrolidinylmethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720689-64-5 CAPLUS
CN 1H-3-Benzazepine, 3-cyclopentyl-2,3,4,5-tetrahydro-7-(4-piperidinylmethoxy)- (CA INDEX NAME)



RN 720690-40-4 CAPLUS
CN Benzoic acid, 4-[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-, methyl ester (CA INDEX NAME)



RN 720690-41-5 CAPLUS
CN Benzoic acid, 4-[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]- (CA INDEX NAME)



RN 720690-46-0 CAPLUS
CN Benzoic acid, 3-[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-, methyl ester (CA INDEX NAME)



RN 720690-47-1 CAPLUS
CN Benzoic acid, 3-[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]- (CA INDEX NAME)



RN 720690-74-4 CAPLUS
CN 2-Pyrazinecarboxylic acid, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, methyl ester (CA INDEX NAME)



RN 720691-00-9 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(3S)-3-pyrrolidinylmethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720691-01-0 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(3S)-3-piperidinylmethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720691-02-1 CAPLUS

CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(3S)-3-piperidinyloxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720691-59-8 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(5-iodo-2-pyridinyl)oxy]- (CA INDEX NAME)



RN 720691-60-1 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(5-nitro-2-pyridinyl)oxy]- (CA INDEX NAME)



RN 720691-63-4 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(5-nitro-2-thienyl)oxy]- (CA INDEX NAME)



RN 720691-66-7 CAPLUS
CN Ethanone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-78-1 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-iodo-8-(phenylmethoxy)- (CA INDEX NAME)



RN 720691-83-8 CAPLUS
CN 2,3-Pyridinedicarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, 2,3-dimethyl ester (CA INDEX NAME)



RN 720691-84-9 CAPLUS
CN 2,3-Pyridinedicarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, sodium salt (1:2) (CA INDEX NAME)



RN 720691-85-0 CAPLUS
CN 5H-Pyrrolo[3,4-b]pyridine-5,7(6H)-dione, 2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720691-86-1 CAPLUS
CN 5H-Pyrrolo[3,4-b]pyridin-5-one, 2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-6,7-dihydro-7-hydroxy- (CA INDEX NAME)



RN 720691-88-3 CAPLUS
CN 3-Pyridinamine, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-09-1 CAPLUS
CN 1H-3-Benzazepine, 7-[(5-chloro-2-pyrazinyl)oxy]-3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720692-11-5 CAPLUS
CN 1H-3-Benzazepine, 7-[(5-bromo-2-pyrazinyl)oxy]-3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720692-24-0 CAPLUS
CN Benzonitrile, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-

yl)oxy]-3-fluoro- (CA INDEX NAME)



RN 720692-25-1 CAPLUS
CN Benzoic acid, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-fluoro- (CA INDEX NAME)



RN 720692-27-3 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-7-(2-fluoro-4-iodophenoxy)-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720693-38-9 CAPLUS
CN 2-Pyridinecarbonitrile, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



IT 720689-65-6P 720689-66-7P 720689-67-8P
720689-68-9P 720689-69-0P 720689-70-3P
720689-71-4P 720689-72-5P 720689-73-6P
720689-74-7P 720689-75-8P 720689-76-9P
720689-77-0P 720689-78-1P 720689-79-2P
720689-80-5P 720689-81-6P 720689-82-7P
720689-83-8P 720689-84-9P 720689-85-0P
720689-86-1P 720689-87-2P 720689-88-3P

720689-89-4P 720689-90-7P 720689-91-8P
720689-92-9P 720689-93-0P 720689-94-1P
720689-95-2P 720689-96-3P 720689-97-4P
720689-98-5P 720689-99-6P 720690-00-6P
720690-01-7P 720690-02-8P 720690-03-9P
720690-04-0P 720690-05-1P 720690-06-2P
720690-07-3P 720690-08-4P 720690-09-5P
720690-10-8P 720690-11-9P 720690-12-0P
720690-13-1P 720690-14-2P 720690-15-3P
720690-16-4P 720690-17-5P 720690-18-6P
720690-19-7P 720690-24-4P 720690-25-5P
720690-26-6P 720690-27-7P 720690-28-8P
720690-29-9P 720690-30-2P 720690-31-3P
720690-32-4P 720690-33-5P 720690-34-6P
720690-35-7P 720690-36-8P 720690-37-9P
720690-38-0P 720690-39-1P 720690-42-6P
720690-43-7P 720690-44-8P 720690-45-9P
720690-48-2P 720690-49-3P 720690-50-6P
720690-51-7P 720690-52-8P 720690-53-9P
720690-54-0P 720690-55-1P 720690-56-2P
720690-57-3P 720690-58-4P 720690-59-5P
720690-60-8P 720690-61-9P 720690-62-0P
720690-63-1P 720690-64-2P 720690-65-3P
720690-66-4P 720690-67-5P 720690-68-6P
720690-69-7P 720690-70-0P 720690-71-1P
720690-72-2P 720690-73-3P 720690-75-5P
720690-76-6P 720690-77-7P 720690-78-8P
720690-79-9P 720690-80-2P 720690-81-3P
720690-82-4P 720690-83-5P 720690-84-6P
720690-85-7P 720690-86-8P 720690-87-9P
720690-88-0P 720690-89-1P 720690-90-4P
720690-91-5P 720690-92-6P 720690-93-7P
720690-94-8P 720690-95-9P 720690-96-0P
720690-97-1P 720690-98-2P 720690-99-3P
720691-04-3P 720691-05-4P 720691-06-5P
720691-07-6P 720691-08-7P 720691-09-8P
720691-10-1P 720691-11-2P 720691-12-3P
720691-13-4P 720691-14-5P 720691-15-6P
720691-16-7P 720691-17-8P 720691-18-9P
720691-19-0P 720691-24-7P 720691-25-8P
720691-26-9P 720691-27-0P 720691-28-1P
720691-29-2P 720691-30-5P 720691-31-6P
720691-32-7P 720691-33-8P 720691-34-9P
720691-35-0P 720691-36-1P 720691-37-2P
720691-38-3P 720691-39-4P 720691-40-7P
720691-41-8P 720691-42-9P 720691-43-0P
720691-44-1P 720691-45-2P 720691-46-3P
720691-47-4P 720691-48-5P 720691-49-6P
720691-50-9P 720691-51-0P 720691-52-1P
720691-53-2P 720691-54-3P 720691-55-4P
720691-56-5P 720691-57-6P 720691-58-7P
720691-61-2P 720691-62-3P 720691-64-5P
720691-65-6P 720691-67-8P 720691-68-9P
720691-69-0P 720691-70-3P 720691-71-4P
720691-72-5P 720691-73-6P 720691-74-7P
720691-75-8P 720691-76-9P 720691-77-0P
720691-79-2P 720691-80-5P 720691-81-6P

720691-82-7P 720691-87-2P 720691-89-4P
720691-90-7P 720691-91-8P 720691-92-9P
720691-93-0P 720691-94-1P 720691-95-2P
720691-96-3P 720691-97-4P 720691-98-5P
720691-99-6P 720692-00-2P 720692-01-3P
720692-02-4P 720692-03-5P 720692-04-6P
720692-05-7P 720692-06-8P 720692-07-9P
720692-08-0P 720692-10-4P 720692-12-6P
720692-13-7P 720692-14-8P 720692-15-9P
720692-17-1P 720692-18-2P 720692-19-3P
720692-20-6P 720692-21-7P 720692-22-8P
720692-23-9P 720692-26-2P 720692-28-4P
720692-29-5P 720692-30-8P 720692-31-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzo[d]azepine derivs. as antagonists and/or inverse agonists of the histamine H3 receptor for the treatment of neurol. disorders)

RN 720689-65-6 CAPLUS
CN Benzonitrile, 4-[[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]carbonyl]- (CA INDEX NAME)



RN 720689-66-7 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720689-67-8 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]cyclohexyl- (CA INDEX NAME)



RN 720689-68-9 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-1-isoquinolinyl- (CA INDEX NAME)



RN 720689-69-0 CAPLUS
CN Benzonitrile, 4-[(1E)-3-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-3-oxo-1-propen-1-yl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 720689-70-3 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-6-isoquinolinyl- (CA INDEX NAME)



RN 720689-71-4 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl](5-methyl-3-isoxazolyl)- (CA INDEX NAME)



RN 720689-72-5 CAPLUS
CN Methanone, 6-benzothiazolyl[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]- (CA INDEX NAME)



RN 720689-73-6 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-4-pyridinyl- (CA INDEX NAME)



RN 720689-74-7 CAPLUS
CN Piperidine, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-[4-(1-pyrrolidinylcarbonyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 720689-75-8 CAPLUS

CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-3-thienyl- (CA INDEX NAME)



RN 720689-76-9 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-3-furanyl- (CA INDEX NAME)



RN 720689-77-0 CAPLUS
CN Methanone, [4-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-piperidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720689-78-1 CAPLUS
CN Methanone, [(2R)-2-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 720689-79-2 CAPLUS
CN Methanone, [(3R)-3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-pyrrolidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 720689-80-5 CAPLUS
CN Methanone, [(3S)-3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-pyrrolidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 720689-81-6 CAPLUS
CN Methanone, [(2S)-2-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 720689-82-7 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl][4-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 720689-83-8 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-2-pyrazinyl- (CA INDEX NAME)



RN 720689-84-9 CAPLUS
CN 2(1H)-Pyridinone, 5-[[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]carbonyl]- (CA INDEX NAME)



RN 720689-85-0 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl](2,3-dihydro-5-benzofuranyl)- (CA INDEX NAME)



RN 720689-86-1 CAPLUS
CN 1-Propanone, 1-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-3-methoxy- (CA INDEX NAME)



RN 720689-87-2 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl](2,3-dihydro-7-benzofuranyl)- (CA INDEX NAME)



RN 720689-88-3 CAPLUS
CN Benzonitrile, 4-[[4-[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-piperidinyl]carbonyl]- (CA INDEX NAME)



RN 720689-89-4 CAPLUS
CN Piperidine, 4-[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-[4-(1-pyrrolidinylcarbonyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 720689-90-7 CAPLUS
CN Benzonitrile, 4-[[4-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]carbonyl]- (CA INDEX NAME)



RN 720689-91-8 CAPLUS
CN Methanone, [4-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-4-pyridinyl- (CA INDEX NAME)



RN 720689-92-9 CAPLUS
CN Methanone, [4-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-6-quinolinyl- (CA INDEX NAME)



RN 720689-93-0 CAPLUS
CN Piperidine, 4-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-

1-[4-(1-pyrrolidinylcarbonyl)benzoyl]- (9CI) (CA INDEX NAME)



RN 720689-94-1 CAPLUS
CN Methanone, [1,1'-biphenyl]-4-yl[4-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]- (CA INDEX NAME)



RN 720689-95-2 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]cyclopentyl- (CA INDEX NAME)



RN 720689-96-3 CAPLUS
CN Benzonitrile, 4-[[4-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-piperidinyl]carbonyl]- (CA INDEX NAME)



RN 720689-97-4 CAPLUS
CN Benzonitrile, 4-[[(2R)-2-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720689-98-5 CAPLUS
CN Benzonitrile, 4-[[(3R)-3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720689-99-6 CAPLUS
CN Benzonitrile, 4-[[(3S)-3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720690-00-6 CAPLUS
CN Benzonitrile, 4-[[(2S)-2-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720690-01-7 CAPLUS
CN 1-Propanone, 1-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-2,2-dimethyl- (CA INDEX NAME)



RN 720690-02-8 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]cyclopropyl- (CA INDEX NAME)



RN 720690-03-9 CAPLUS
CN Methanone, cyclobutyl[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]- (CA INDEX NAME)



RN 720690-04-0 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-

1-piperidinyl]-4-morpholinyl- (CA INDEX NAME)



RN 720690-05-1 CAPLUS
CN Methanone, [4-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-piperidinyl]-4-morpholinyl- (CA INDEX NAME)



RN 720690-06-2 CAPLUS
CN Methanone, [(2R)-2-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl]-4-morpholinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 720690-07-3 CAPLUS
CN Methanone, [(3R)-3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-pyrrolidinyl]-4-morpholinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 720690-08-4 CAPLUS
CN Methanone, [(3S)-3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-pyrrolidinyl]-4-morpholinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 720690-09-5 CAPLUS
CN 1-Piperidinecarboxamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-bis(1-methylethyl)- (CA INDEX NAME)



RN 720690-10-8 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 720690-11-9 CAPLUS
CN Piperidine, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-(1-piperidinylcarbonyl)- (9CI) (CA INDEX NAME)



RN 720690-12-0 CAPLUS
CN Methanone, [(2S)-2-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl]-4-morpholinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 720690-13-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-diethyl- (CA INDEX NAME)



RN 720690-14-2 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl](1,3-dihydro-2H-isoindol-2-yl)- (CA INDEX NAME)



RN 720690-15-3 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl][4-(2-pyrazinyl)-1-piperazinyl]- (CA INDEX NAME)



RN 720690-16-4 CAPLUS
CN 1-Piperidinecarboxamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(2-methoxyethyl)-N-(1-methylethyl)- (CA INDEX NAME)



RN 720690-17-5 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl](1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)



RN 720690-18-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-

benzazepin-7-yl)oxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 720690-19-7 CAPLUS
CN 1-Piperidinecarboxamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(4-fluorophenyl)- (CA INDEX NAME)



RN 720690-24-4 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[1-(methylsulfonyl)-4-piperidinyl]oxy]- (CA INDEX NAME)



RN 720690-25-5 CAPLUS
CN Benzonitrile, 4-[[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)



RN 720690-26-6 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-7-[[1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-piperidinyl]oxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720690-27-7 CAPLUS
CN Benzonitrile, 4-[[4-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-piperidinyl]sulfonyl]- (CA INDEX NAME)



RN 720690-28-8 CAPLUS
CN Benzonitrile, 4-[[(2R)-2-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720690-29-9 CAPLUS
CN Benzonitrile, 4-[[(3R)-3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-pyrrolidinyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720690-30-2 CAPLUS
CN Benzonitrile, 4-[[(3S)-3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-pyrrolidinyl]sulfonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720690-31-3 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-7-[(2,4-difluorophenyl)methoxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720690-32-4 CAPLUS
CN Benzonitrile, 3-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]- (CA INDEX NAME)



RN 720690-33-5 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(3-methoxyphenyl)methoxy]- (CA INDEX NAME)



RN 720690-34-6 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(2-pyridinylmethoxy)-
(CA INDEX NAME)



RN 720690-35-7 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(3-pyridinylmethoxy)-
(CA INDEX NAME)



RN 720690-36-8 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(4-pyridinylmethoxy)-
(CA INDEX NAME)



RN 720690-37-9 CAPLUS
CN Benzonitrile, 2-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-
yl)oxy]methyl]- (CA INDEX NAME)



RN 720690-38-0 CAPLUS
CN Benzonitrile, 4-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]- (CA INDEX NAME)



RN 720690-39-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-methyl- (CA INDEX NAME)



RN 720690-42-6 CAPLUS
CN Methanone, [4-[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 720690-43-7 CAPLUS
CN Methanone, [4-[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]phenyl]-4-morpholinyl- (CA INDEX NAME)



RN 720690-44-8 CAPLUS

CN Methanone, [4-[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]phenyl][4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)



RN 720690-45-9 CAPLUS
CN Methanone, [4-[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]phenyl][4-(4-fluorophenyl)-1-piperazinyl]- (CA INDEX NAME)



RN 720690-48-2 CAPLUS
CN Methanone, [3-[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 720690-49-3 CAPLUS
CN Methanone, [3-[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]phenyl]-4-morpholinyl- (CA INDEX NAME)



RN 720690-50-6 CAPLUS
CN Methanone, [3-[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]phenyl][4-(4-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)



RN 720690-51-7 CAPLUS
CN Methanone, [3-[[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]phenyl][4-(4-fluorophenyl)-1-piperazinyl]- (CA INDEX NAME)



RN 720690-52-8 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720690-53-9 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(2-pyridinyloxy)- (CA INDEX NAME)



RN 720690-54-0 CAPLUS
CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-4-morpholinyl- (CA INDEX NAME)



RN 720690-55-1 CAPLUS
CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 720690-56-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720690-57-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-dimethyl- (CA INDEX NAME)



RN 720690-58-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-methyl- (CA INDEX NAME)



RN 720690-59-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-cyclopentyl- (CA INDEX NAME)



RN 720690-60-8 CAPLUS
CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-1-piperidinyl- (CA INDEX NAME)



RN 720690-61-9 CAPLUS
CN Methanone, [2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-4-pyridinyl]-1-piperidinyl- (CA INDEX NAME)



RN 720690-62-0 CAPLUS
CN Methanone, [2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-4-pyridinyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 720690-63-1 CAPLUS
CN Methanone, [2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-4-pyridinyl]-4-morpholinyl- (CA INDEX NAME)



RN 720690-64-2 CAPLUS
CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]-1-piperidinyl- (CA INDEX NAME)



RN 720690-65-3 CAPLUS
CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl](1,1-dioxido-4-thiomorpholinyl)- (CA INDEX NAME)



RN 720690-66-4 CAPLUS
CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 720690-67-5 CAPLUS
CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]-4-morpholinyl- (CA INDEX NAME)



RN 720690-68-6 CAPLUS
CN Methanone, [2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-4-morpholinyl- (CA INDEX NAME)



RN 720690-69-7 CAPLUS
CN Methanone, [2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-1-piperidinyl- (CA INDEX NAME)



RN 720690-70-0 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(2-pyrazinyloxy)- (CA INDEX NAME)



RN 720690-71-1 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(2-pyrimidinyloxy)- (CA INDEX NAME)



RN 720690-72-2 CAPLUS
CN 1H-3-Benzazepine, 7-[(5-bromo-2-pyrimidinyl)oxy]-3-cyclobutyl-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720690-73-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720690-75-5 CAPLUS
CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]-4-morpholinyl- (CA INDEX NAME)



RN 720690-76-6 CAPLUS
CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-methyl- (CA INDEX NAME)



RN 720690-77-7 CAPLUS
CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720690-78-8 CAPLUS
CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]-1-piperidinyl- (CA INDEX NAME)



RN 720690-79-9 CAPLUS
CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 720690-80-2 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-phenoxy- (CA INDEX NAME)



RN 720690-81-3 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]phenyl]-4-morpholinyl- (CA INDEX NAME)



RN 720690-82-4 CAPLUS
CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 720690-83-5 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 720690-84-6 CAPLUS
CN Benzamide, N-cyclobutyl-4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720690-85-7 CAPLUS
CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-diethyl- (CA INDEX NAME)



RN 720690-86-8 CAPLUS
CN Benzamide, N-(2-cyanoethyl)-4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720690-87-9 CAPLUS
CN Methanone, [3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]phenyl]-4-morpholinyl- (CA INDEX NAME)



RN 720690-88-0 CAPLUS
CN Benzamide, 3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 720690-89-1 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[4-(4-morpholinylsulfonyl)phenoxy]- (CA INDEX NAME)



RN 720690-90-4 CAPLUS
CN Benzenesulfonamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-diethyl- (CA INDEX NAME)



RN 720690-91-5 CAPLUS
CN 1H-3-Benzazepine, 3-cyclohexyl-2,3,4,5-tetrahydro-7-(phenylmethoxy)- (CA INDEX NAME)



RN 720690-92-6 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[2-(1-piperidinyl)-5-pyrimidinyl]oxy]- (CA INDEX NAME)



RN 720690-93-7 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[2-(1-pyrrolidinyl)-5-pyrimidinyl]oxy]- (CA INDEX NAME)



RN 720690-94-8 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-7-[[2-(1,1-dioxido-4-thiomorpholinyl)-5-pyrimidinyl]oxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720690-95-9 CAPLUS
CN 2-Pyrimidinamine, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720690-96-0 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(2-methoxy-5-

pyrimidinyl)oxy]- (CA INDEX NAME)



RN 720690-97-1 CAPLUS
CN 2-Pyrrolidinone, 1-[4-[[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]carbonyl]phenyl]- (CA INDEX NAME)



RN 720690-98-2 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl][3-(methylsulfonyl)phenyl]- (CA INDEX NAME)



RN 720690-99-3 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl](3,4-dihydro-1,1-dioxido-2H-1-benzothiopyran-6-yl)- (CA INDEX NAME)



RN 720691-04-3 CAPLUS
CN Methanone, [(3S)-3-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-piperidinyl]-4-morpholinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 720691-05-4 CAPLUS
CN Methanone, [(3S)-3-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl]-4-morpholinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 720691-06-5 CAPLUS
CN Methanone, [(3S)-3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-4-morpholinyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 720691-07-6 CAPLUS
CN Benzonitrile, 4-[[(3S)-3-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-piperidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720691-08-7 CAPLUS
CN Benzonitrile, 4-[[(3S)-3-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720691-09-8 CAPLUS
CN Benzonitrile, 4-[[(3S)-3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]carbonyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 720691-10-1 CAPLUS
CN Methanone, [(3S)-3-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-pyrrolidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 720691-11-2 CAPLUS
CN Methanone, [(3S)-3-[[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-1-piperidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 720691-12-3 CAPLUS
CN Methanone, [(3S)-3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl](tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 720691-13-4 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]- (CA INDEX NAME)



RN 720691-14-5 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 720691-15-6 CAPLUS
CN Methanone, 1-azetidinyl[6-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-16-7 CAPLUS
CN Methanone, [6-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-3-pyridinyl]-4-morpholinyl- (CA INDEX NAME)



RN 720691-17-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]-N-methyl- (CA INDEX NAME)



RN 720691-18-9 CAPLUS
CN 4-Pyridinecarbonitrile, 2-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl]- (CA INDEX NAME)



RN 720691-19-0 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[1-(2-pyrazinyl)-4-piperidinyl]oxy]- (CA INDEX NAME)



RN 720691-24-7 CAPLUS
CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 720691-25-8 CAPLUS
CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720691-26-9 CAPLUS
CN Methanone, 1-azetidinyl[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]- (CA INDEX NAME)



RN 720691-27-0 CAPLUS
CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-diethyl- (CA INDEX NAME)



RN 720691-28-1 CAPLUS
CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 720691-29-2 CAPLUS
CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl- (CA INDEX NAME)



RN 720691-30-5 CAPLUS
CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrimidinyl]-4-morpholinyl- (CA INDEX NAME)



RN 720691-31-6 CAPLUS
CN 2-Pyrimidinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(cyclopropylmethyl)- (CA INDEX NAME)



RN 720691-32-7 CAPLUS
CN 2-Pyrimidinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl- (CA INDEX NAME)



RN 720691-33-8 CAPLUS
CN Methanone, 1-azetidinyl[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrimidinyl]- (CA INDEX NAME)



RN 720691-34-9 CAPLUS
CN 2-Pyrimidinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-methyl- (CA INDEX NAME)



RN 720691-35-0 CAPLUS
CN 2-Pyrimidinecarboxamide, N-cyclobutyl-5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720691-36-1 CAPLUS
CN 2-Pyrimidinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720691-37-2 CAPLUS
CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrimidinyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 720691-38-3 CAPLUS
CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrimidinyl]-1-piperidinyl- (CA INDEX NAME)



RN 720691-39-4 CAPLUS
CN 2-Pyrimidinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720691-40-7 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720691-41-8 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl- (CA INDEX NAME)



RN 720691-42-9 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-methyl- (CA INDEX NAME)



RN 720691-43-0 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-diethyl- (CA INDEX NAME)



RN 720691-44-1 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 720691-45-2 CAPLUS
CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 720691-46-3 CAPLUS
CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl]-4-morpholinyl- (CA INDEX NAME)



RN 720691-47-4 CAPLUS
CN Methanone, [5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyridinyl](tetrahydro-1,4-oxazepin-4(5H)-yl)- (CA INDEX NAME)



RN 720691-48-5 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-cyclopentyl- (CA INDEX NAME)



RN 720691-49-6 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-cyclopropyl- (CA INDEX NAME)



RN 720691-50-9 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 720691-51-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-

7-yl)oxy]-N-ethyl- (CA INDEX NAME)



RN 720691-52-1 CAPLUS
CN 3-Pyridinecarboxamide, N-cyclobutyl-6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720691-53-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



RN 720691-54-3 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,N-diethyl- (CA INDEX NAME)



RN 720691-55-4 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 720691-56-5 CAPLUS
CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-(2-methoxyethyl)- (CA INDEX NAME)



RN 720691-57-6 CAPLUS
CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720691-58-7 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(3-pyridinyloxy)- (CA INDEX NAME)



RN 720691-61-2 CAPLUS
CN Acetamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-62-3 CAPLUS
CN Acetamide, N-[2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-5-thiazolyl]- (CA INDEX NAME)



RN 720691-64-5 CAPLUS
CN Acetamide, N-[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-thienyl]- (CA INDEX NAME)



RN 720691-65-6 CAPLUS
CN 2(1H)-Pyridinone, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720691-67-8 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(1H-pyrazol-3-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 720691-68-9 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(5-methyl-1,3,4-oxadiazol-2-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 720691-69-0 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-70-3 CAPLUS
CN 2-Piperidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-71-4 CAPLUS
CN 2-Azetidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-72-5 CAPLUS
CN 2-Oxazolidinone, 3-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-73-6 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(1H-pyrazol-1-yl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 720691-74-7 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-7-[[5-(3,5-dimethyl-4-isoxazolyl)-2-pyridinyl]oxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720691-75-8 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720691-76-9 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-6-[[2,3,4,5-tetrahydro-3-(2-methylcyclopentyl)-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)



RN 720691-77-0 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-8-iodo-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720691-79-2 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(4-methoxy-6-methyl-2-quinolinyl)oxy]- (CA INDEX NAME)



RN 720691-80-5 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(4-methoxy-1,7-naphthyridin-2-yl)oxy]- (CA INDEX NAME)



RN 720691-81-6 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-(1,5-naphthyridin-2-yloxy)- (CA INDEX NAME)



RN 720691-82-7 CAPLUS
CN Acetamide, N-[7-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-6-methyl-1,8-naphthyridin-2-yl]- (CA INDEX NAME)



RN 720691-87-2 CAPLUS
CN 5H-Pyrrolo[3,4-b]pyridin-5-one, 2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-6,7-dihydro- (CA INDEX NAME)



RN 720691-89-4 CAPLUS
CN 4-Morpholinecarboxamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-90-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-91-8 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720691-92-9 CAPLUS
CN Propanamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-2-methyl- (CA INDEX NAME)



RN 720691-93-0 CAPLUS
CN 2H-Pyran-4-carboxamide, N-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]tetrahydro- (CA INDEX NAME)



RN 720691-94-1 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-7-[[5-(4,6-dimethoxy-2-pyrimidinyl)-2-pyridinyl]oxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720691-95-2 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-[4-(methylsulfonyl)phenyl]-2-pyrazinyl]oxy]- (CA INDEX NAME)



RN 720691-96-3 CAPLUS
CN Acetamide, N-[4-[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]phenyl]- (CA INDEX NAME)



RN 720691-97-4 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-7-[(3,5-dimethyl-2-pyridinyl)oxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720691-98-5 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[5-(4-morpholinylsulfonyl)-2-pyridinyl]oxy]- (CA INDEX NAME)



RN 720691-99-6 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(2-methylfuro[2,3-c]pyridin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-00-2 CAPLUS
CN 3-Pyridinecarbonitrile, 2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-4-ethoxy- (CA INDEX NAME)



RN 720692-01-3 CAPLUS
CN 3-Pyridinecarbonitrile, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-methyl- (CA INDEX NAME)



RN 720692-02-4 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-5-methyl- (CA INDEX NAME)



RN 720692-03-5 CAPLUS
CN 2-Imidazolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-3-methyl- (CA INDEX NAME)



RN 720692-04-6 CAPLUS
CN 2-Pyrrolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-4-hydroxy-, (4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 720692-05-7 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-6-[[2,3,4,5-tetrahydro-3-(3-methylcyclopentyl)-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)



RN 720692-06-8 CAPLUS
CN 2-Pyrazinecarboxamide, 5-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720692-07-9 CAPLUS
CN 2-Pyrazinecarboxamide, N-methyl-5-[[2,3,4,5-tetrahydro-3-(3-methylcyclopentyl)-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)



RN 720692-08-0 CAPLUS
CN 2-Pyrrolidinone, 1-[3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]- (CA INDEX NAME)



RN 720692-10-4 CAPLUS
CN 2-Pyrrolidinone, 1-[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]- (CA INDEX NAME)



RN 720692-12-6 CAPLUS
CN 2-Oxazolidinone, 3-[5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-2-pyrazinyl]- (CA INDEX NAME)



RN 720692-13-7 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-7-[[5-(1,1-dioxido-2-isothiazolidinyl)-2-pyridinyl]oxy]-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720692-14-8 CAPLUS
CN 2-Imidazolidinone, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]- (CA INDEX NAME)



RN 720692-15-9 CAPLUS
CN 2-Pyrazinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-17-1 CAPLUS
CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-methoxy-N-methyl- (CA INDEX NAME)



RN 720692-18-2 CAPLUS
CN Benzonitrile, 2-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-19-3 CAPLUS
CN Benzamide, 3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-4-methoxy-N-methyl- (CA INDEX NAME)



RN 720692-20-6 CAPLUS
CN Benzamide, 3-chloro-4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720692-21-7 CAPLUS
CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N,3-dimethyl- (CA INDEX NAME)



RN 720692-22-8 CAPLUS

CN 1H-3-Benzazepine-7-carbonitrile, 3-cyclobutyl-2,3,4,5-tetrahydro-8-(phenylmethoxy)- (CA INDEX NAME)



RN 720692-23-9 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-7-(2-fluorophenoxy)-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720692-26-2 CAPLUS
CN Benzamide, 4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-fluoro-N-methyl- (CA INDEX NAME)



RN 720692-28-4 CAPLUS
CN 2-Pyrrolidinone, 1-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-fluorophenyl]- (CA INDEX NAME)



RN 720692-29-5 CAPLUS
CN Acetamide, N-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-fluorophenyl]- (CA INDEX NAME)



RN 720692-30-8 CAPLUS
CN Methanone, [3-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]phenyl]-1-pyrrolidinyl- (CA INDEX NAME)



RN 720692-31-9 CAPLUS
CN 2-Pyridinecarboxamide, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)



IT 720692-32-0P 720692-33-1P 720692-34-2P
720692-35-3P 720692-38-6P 720692-39-7P
720692-40-0P 720692-41-1P 720692-42-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzo[d]azepine derivs. as antagonists and/or inverse agonists of the histamine H3 receptor for the treatment of neurol. disorders)

RN 720692-32-0 CAPLUS
CN Benzamide, 3-cyano-4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720692-33-1 CAPLUS

CN Methanone, [6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridazinyl]-4-morpholinyl- (CA INDEX NAME)



RN 720692-34-2 CAPLUS
CN 3-Pyridazinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl- (CA INDEX NAME)



RN 720692-35-3 CAPLUS
CN 3-Pyridazinecarboxamide, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-ethyl-N-methyl- (CA INDEX NAME)



RN 720692-38-6 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl][4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 720692-39-7 CAPLUS
CN Ethanone, 1-[4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-

1-piperidinyl]-2-cyclopropyl- (CA INDEX NAME)



RN 720692-40-0 CAPLUS
CN Methanone, [4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-1-piperidinyl][(2R,6S)-2,6-dimethyl-4-morpholinyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 720692-41-1 CAPLUS
CN Methanone, [trans-4-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]cyclohexyl]-4-morpholinyl- (CA INDEX NAME)

Relative stereochemistry.



RN 720692-42-2 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[[6-(4-morpholinyl)-2-pyrazinyl]oxy]- (CA INDEX NAME)



IT 720692-43-3P 720692-44-4P 720692-45-5P
720692-47-7P 720692-48-8P 720692-49-9P
720692-51-3P 720692-52-4P 720692-54-6P
720692-55-7P 720692-56-8P 720692-57-9P
720692-58-0P 720692-59-1P 720692-62-6P
720692-63-7P 720692-64-8P 720692-68-2P
720692-69-3P 720692-70-6P 720692-71-7P
720692-72-8P 720692-73-9P 720692-74-0P
720692-78-4P 720692-79-5P 720692-80-8P
720692-81-9P 720692-82-0P 720692-83-1P
720692-84-2P 720692-85-3P 720692-86-4P
720692-87-5P 720692-88-6P 720692-89-7P
720692-90-0P 720692-92-2P 720692-93-3P
720692-94-4P 720692-95-5P 720692-96-6P
720692-97-7P 720692-98-8P 720692-99-9P
720693-02-7P 720693-03-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzo[d]azepine derivs. as antagonists and/or inverse agonists of the histamine H3 receptor for the treatment of neurol. disorders)

RN 720692-43-3 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-(phenylmethoxy)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-44-4 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-(phenylmethoxy)- (CA INDEX NAME)



RN 720692-45-5 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[4-(methoxycarbonyl)phenyl]methoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-47-7 CAPLUS
CN Benzoic acid, 4-[[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-, methyl ester (CA INDEX NAME)



RN 720692-48-8 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[5-[(methylamino)carbonyl]-2-pyridinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-49-9 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-6-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-51-3 CAPLUS
CN 3-Pyridinecarboxamide, N-methyl-6-[(2,3,4,5-tetrahydro-8-iodo-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-52-4 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-iodo-8-(phenylmethoxy)- (CA INDEX NAME)



RN 720692-54-6 CAPLUS
CN 2-Pyrazinecarboxamide, N-methyl-5-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-55-7 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[5-(methoxycarbonyl)-2-pyrazinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-56-8 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[(5-carboxy-2-pyrazinyl)oxy]-1,2,4,5-tetrahydro-, 3-(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 720692-57-9 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[5-[(methylamino)carbonyl]-2-pyrazinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-58-0 CAPLUS
CN 2-Propen-1-one, 1-[6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-3-pyridinyl]-3-(dimethylamino)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 720692-59-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, hydrazide (CA INDEX NAME)



RN 720692-62-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(3-cyclopentyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-63-7 CAPLUS
CN 2-Pyrazinecarboxylic acid, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-64-8 CAPLUS
CN 2-Pyrazinecarbonyl chloride, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-68-2 CAPLUS
CN 2-Pyrimidinecarbonitrile, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-69-3 CAPLUS
CN 2-Pyrimidinecarboxylic acid, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-70-6 CAPLUS
CN 2-Pyridinecarboxylic acid, 5-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-71-7 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-, methyl ester (CA INDEX NAME)



RN 720692-72-8 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-73-9 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(5-nitro-2-thiazolyl)oxy]- (CA INDEX NAME)



RN 720692-74-0 CAPLUS
CN 1H-3-Benzazepine, 3-cyclobutyl-2,3,4,5-tetrahydro-7-[(6-methoxy-3-pyridinyl)oxy]- (CA INDEX NAME)



RN 720692-78-4 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[2-methoxy-4-(methoxycarbonyl)phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-79-5 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-(4-carboxy-2-methoxyphenoxy)-1,2,4,5-tetrahydro-, 3-(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 720692-80-8 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[2-methoxy-4-[(methylamino)carbonyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-81-9 CAPLUS
CN Benzamide, 3-methoxy-N-methyl-4-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-82-0 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[2-methoxy-5-(methoxycarbonyl)phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-83-1 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-(5-carboxy-2-methoxyphenoxy)-1,2,4,5-tetrahydro-, 3-(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 720692-84-2 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[2-methoxy-5-[(methylamino)carbonyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-85-3 CAPLUS
CN Benzamide, 4-methoxy-N-methyl-3-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-86-4 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[2-chloro-4-(methoxycarbonyl)phenoxy]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-87-5 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-(4-carboxy-2-chlorophenoxy)-1,2,4,5-tetrahydro-, 3-(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 720692-88-6 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[2-chloro-4-[(methylamino)carbonyl]phenoxy]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-89-7 CAPLUS
CN Benzamide, 3-chloro-N-methyl-4-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-90-0 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[4-(methoxycarbonyl)-2-methylphenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-92-2 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-(4-carboxy-2-methylphenoxy)-1,2,4,5-tetrahydro-, 3-(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 720692-93-3 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[2-methyl-4-[(methylamino)carbonyl]phenoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-94-4 CAPLUS
CN Benzamide, N,3-dimethyl-4-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



RN 720692-95-5 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-(2-fluoro-4-nitrophenoxy)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-96-6 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-(4-amino-2-fluorophenoxy)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-97-7 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-(2-fluoro-4-iodophenoxy)-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720692-98-8 CAPLUS
CN 1H-3-Benzazepine, 7-(2-fluoro-4-iodophenoxy)-2,3,4,5-tetrahydro- (CA INDEX NAME)



RN 720692-99-9 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[4-(acetylamino)-2-fluorophenoxy]-

1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720693-02-7 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[2-cyano-4-[(methylamino)carbonyl]phenoxy]-1,2,4,5-tetrahydro-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 720693-03-8 CAPLUS
CN Benzamide, 3-cyano-N-methyl-4-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



L12 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:354915 CAPLUS
DOCUMENT NUMBER: 140:375086
TITLE: A preparation of benzo[d]azepine derivatives as a histamine H3 receptor antagonists useful for the treatment of neurological and psychiatric disorders
INVENTOR(S): Heightman, Thomas Daniel; Wilson, David Matthew
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035544	A1	20040429	WO 2003-EP11421	20031014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003278084	A1	20040504	AU 2003-278084	20031014
PRIORITY APPLN. INFO.:			GB 2002-24083 A	20021016
			WO 2003-EP11421 W	20031014

OTHER SOURCE(S): MARPAT 140:375086
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to novel benzoazepine derivs. of formula I [wherein: R1 = H, (un)substituted (cyclo)alkyl, (hetero)aryl, or alkyl-aryl, etc.; R2 = H, alkyl, alkoxy, CN, NH2, or CF3; R3 represents -(CH2)2-4-NR4R5 or a group of formula II; R4 and R5 independently represent alkyl or, together with the nitrogen atom to which they are attached, represent an N-linked nitrogen-containing (un)substituted heterocycle; X represents bond, alkyl, C(O), or SO2, etc.; Z = (CH2)0-3; Y = (CH2)0-2; R6 = H, (cyclo)alkyl, alkyl-aryl, or heterocyclyl; R7 = halogen, (halo)alkyl, or OH, etc.] useful for the treatment of neurol. and psychiatric disorders. The invented compds. were screened for histamine H3 receptor activity (histamine H3 binding assay and functional antagonist assay). The prepared compds. exhibited antagonism in the range 6.0-10.0 pKb. For instance, compound III (8.0-10.0 pKb) was prepared via decarboxylation of the prepared benzoazepine IV by treatment with CF3CO2H in CH2Cl2 at 0 °C (example 1, no yield data).

IT 684250-58-6P, 7-[[1-(1-Methylethyl)-4-piperidinyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of benzo[d]azepine derivs. useful for treatment of neurol. and psychiatric disorders)

RN 684250-58-6 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[[1-(1-methylethyl)-4-piperidinyl]oxy]- (CA INDEX NAME)



IT 684250-59-7P, 7-[[1-(1-Methylethyl)-4-piperidinyl]oxy]-3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine 684250-61-1P, 3-Cyclopropylmethyl-7-[(1-isopropylpiperidin-4-yl)oxy]-2,3,4,5-tetrahydro-1H-benzo[d]azepine 684250-62-2P, 7-[[[1-(1-Methylethyl)-4-piperidinyl]methyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzo[d]azepine derivs. useful for treatment of neurol. and psychiatric disorders)

RN 684250-59-7 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[[1-(1-methylethyl)-4-piperidinyl]oxy]-3-(phenylmethyl)- (CA INDEX NAME)



RN 684250-61-1 CAPLUS
CN 1H-3-Benzazepine, 3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-7-[[1-(1-methylethyl)-4-piperidinyl]oxy]- (CA INDEX NAME)



RN 684250-62-2 CAPLUS
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[[1-(1-methylethyl)-4-piperidinyl]methoxy]- (CA INDEX NAME)



IT 684250-25-7P, 1,1-Dimethylethyl 7-[[1-[(2-propen-1-yloxy)carbonyl]-4-piperidinyl]oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 684250-26-8P, 1,1-Dimethylethyl 7-(4-piperidinyloxy)-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 684250-27-9P, 1,1-Dimethylethyl 7-[[1-(1-methylethyl)-4-piperidinyl]oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 684250-28-0P, 1,1-Dimethylethyl 7-[[[1-[(2-propen-1-yloxy)carbonyl]-4-piperidinyl]methyl]oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 684250-29-1P, 1,1-Dimethylethyl 7-[(4-piperidinylmethyl)oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 684250-30-4P, 1,1-Dimethylethyl 7-[[[1-(1-methylethyl)-4-piperidinyl]methyl]oxy]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzo[d]azepine derivs. useful for treatment of neurol. and psychiatric disorders)

RN 684250-25-7 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[1-[(2-propen-1-yloxy)carbonyl]-4-piperidinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 684250-26-8 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-(4-piperidinyloxy)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 684250-27-9 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[1-(1-methylethyl)-4-piperidinyl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 684250-28-0 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[1-[(2-propen-1-yloxy)carbonyl]-4-piperidinyl]methoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 684250-29-1 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-(4-piperidinylmethoxy)-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 684250-30-4 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[1-(1-methylethyl)-4-piperidinyl]methoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 684250-60-0P, 3-[(3,4-Dichlorophenyl)methyl]-7-[[1-(1-methylethyl)-4-piperidinyl]oxy]-2,3,4,5-tetrahydro-1H-3-benzazepine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(reactant; preparation of benzo[d]azepine derivs. useful for treatment of neurol. and psychiatric disorders)
RN 684250-60-0 CAPLUS
CN 1H-3-Benzazepine, 3-[(3,4-dichlorophenyl)methyl]-2,3,4,5-tetrahydro-7-[[1-(1-methylethyl)-4-piperidinyl]oxy]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:267241 CAPLUS
DOCUMENT NUMBER: 140:303538
TITLE: Preparation of [[(aminoalkyl)aryl]oxy]nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions
INVENTOR(S): Blanco-Pillado, Maria-Jesus; Chappell, Mark Donald; Garcia De la Torre, Marta; Diaz Buezo, Nuria; Fritz, James Erwin; Holloway, William Glen; Matt, James Edward, Jr.; Mitch, Charles Howard; Pedregal-Tercero, Concepcion; Quimby, Steven James; Siegel, Miles Goodman; Smith, Dana Rae; Stucky, Russell Dean; Takeuchi, Kumiko; Thomas, Elizabeth Marie; Wolfe, Chad Nolan
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 559 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026305	A1	20040401	WO 2003-US26300	20030917
WO 2004026305	A9	20040513		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499690	A1	20040401	CA 2003-2499690	20030917
AU 2003269980	A1	20040408	AU 2003-269980	20030917
BR 2003014308	A	20050705	BR 2003-14308	20030917
EP 1562595	A1	20050817	EP 2003-751877	20030917
EP 1562595	B1	20080521		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1681498	A	20051012	CN 2003-822241	20030917
JP 2006511474	T	20060406	JP 2004-537682	20030917
NZ 538459	A	20080430	NZ 2003-538459	20030917
AT 395915	T	20080615	AT 2003-751877	20030917
TW 287012	B	20070921	TW 2003-92125729	20030918
US 20060217372	A1	20060928	US 2005-526960	20050303
US 7381719	B2	20080603		
MX 2005PA03093	A	20050713	MX 2005-PA3093	20050318
IN 2005KN00457	A	20060303	IN 2005-KN457	20050318
NO 2005001871	A	20050418	NO 2005-1871	20050418
PRIORITY APPLN. INFO.:			US 2002-412158P P	20020919
			WO 2003-US26300 W	20030917

OTHER SOURCE(S): MARPAT 140:303538
GI



I



II

AB Title diaryl ethers I [wherein X1-X10 = independently C, CH, or N; provided that each of rings A or B has no more than 2 N atoms; E = O or NH; R1 and R2 = independently H or (un)substituted (cyclo)alkyl, alkenyl, alkynyl, (alkyl)aryl, (aryl)heterocyclyl, (cyclo)alkylheterocyclyl, (cyclo)alkanoylalkyl, aroylalkyl, aryloxyalkyl, benzhydryl, bicyclyl(alkyl), benzoyl(alkyl), alkoxyalkyl, alkoxycarbonyl, (aryl)alkylsulfonyl, heterocyclylalkylsulfonyl, cycloalkylalkyl, carboxyalkyl, carbamoylalkyl, etc.; R3 and R3' = independently H, alkyl, alkenyl, alkynyl, (alkyl)aryl, or alkylcycloalkyl; R4 and R5 = independently H, (halo)alkyl, alkenyl, alkynyl, alkoxy(halo)alkyl, thioalkyl, halo, aryl(alkyl), alkanoyl, alkoxycarbonyl, aminoalkyl, cycloalkylalkyl, etc.; R6 and R7 = independently H, (cyclo)alkyl, alkenyl, alkynyl, alkanoyl, OH, alkoxy, (aryl)alkylsulfonyl, heterocyclylalkylsulfonyl, aryl(alkyl), carbamoyl(alkyl), etc.; m = 1-3; n = 0-3; p = 0-3; or pharmaceutically acceptable salts, solvates, enantiomers, racemates, diastereomers, or mixts. thereof] were prepared as μ-, κ-, and δ-opioid receptor antagonists. For example, reductive amination of 6-(2-fluoro-4-formylphenoxy)nicotinamide and 3-methylbutylamine provided II (99%). The latter inhibited ex vivo binding of [3H]-diprenorphine in rat striatum/nucleus accumbens by >65% at a concentration of 7 mg/kg. In an acute feeding rat obesity assay, II suppressed opioid receptors at a dose of 0.3 μg/kg. In addition, diet-induced obese rats achieved an energy balance (caloric intake minus utilization) of −81 kcal/kg/day upon administration of 0.3 mg/kg p.o. of II in an indirect calorimetry assay. Thus, I and their pharmaceutical compns. are useful for the treatment, prevention, or amelioration of obesity and related diseases.

IT 676496-19-8P, 6-[[3-(2,2,2-Trifluoroacetyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl]oxy]nicotinamide 676496-20-1P, 6-[(2,3,4,5-Tetrahydro-1H-benzo[d]azepin-7-yl)oxy]nicotinamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (aryloxy)nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions)

RN 676496-19-8 CAPLUS

CN 3-Pyridinecarboxamide, 6-[[2,3,4,5-tetrahydro-3-(2,2,2-trifluoroacetyl)-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)



RN 676496-20-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)



IT 676496-18-7P, 6-[(3-Phenethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)oxy]nicotinamide 676496-21-2P, 6-[(3-Benzyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)oxy]nicotinamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(opioid receptor antagonist; preparation of (aryloxy)nicotinamides and analogs as opioid receptor antagonist for treatment of obesity and related conditions)

RN 676496-18-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[2,3,4,5-tetrahydro-3-(2-phenylethyl)-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)



RN 676496-21-2 CAPLUS
CN 3-Pyridinecarboxamide, 6-[[2,3,4,5-tetrahydro-3-(phenylmethyl)-1H-3-benzazepin-7-yl]oxy]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:517098 CAPLUS
DOCUMENT NUMBER: 119:117098
ORIGINAL REFERENCE NO.: 119:21055a,21058a
TITLE: Preparation of 2-pyrrolidinone-3-acetates and analogs as cell aggregation inhibitors
INVENTOR(S): Austel, Volkhard; Eisert, Wolfgang; Himmelsbach, Frank; Linz, Guenter; Mueller, Thomas; Pieper, Helmut; Weisenberger, Johannes
PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Germany
SOURCE: Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 528369	A2	19930224	EP 1992-113877	19920814
EP 528369	A3	19930421		
EP 528369	B1	19991124		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4127404	A1	19930225	DE 1991-4127404	19910819
AT 186906	T	19991215	AT 1992-113877	19920814
CA 2076311	A1	19930220	CA 1992-2076311	19920818
NO 9203235	A	19930222	NO 1992-3235	19920818
AU 9221119	A	19930225	AU 1992-21119	19920818
AU 654372	B2	19941103		
JP 06025227	A	19940201	JP 1992-219149	19920818
ZA 9206205	A	19940218	ZA 1992-6205	19920818
IL 102847	A	19961114	IL 1992-102847	19920818
US 5455348	A	19951003	US 1993-173603	19931223
PRIORITY APPLN. INFO.:			DE 1991-4127404 A	19910819
			US 1992-929870 B1	19920814

OTHER SOURCE(S): MARPAT 119:117098
GI



I

AB EYAX1X2X3X4X5B [A = (substituted) bivalent (oxo)alkyleneimino; B = NH2, C(:NH)NH2, NHC(:NH)NH2, etc.; E = CO2H, alkoxycarbonyl, etc.; X1 = bond, alkylene; X2 = bond, O, NH, SO2NH, etc.; X3, X5 = (hetero)cycloalkylene, (hetero)arylene, etc.; X4 = bond, O, CH2, CO, NH, etc.; X3X4X5 = phenylene, (CH2)3-5, etc.; Y = alkylene, NHCH2, OCH2, etc.] were prepared Thus, 4-(5-cyano-2-pyridyl)phenol (preparation given) was condensed with (3S,5S)-3-[(tert-butyloxycarbonyl)methyl]-5-[(methanesulfonyloxy)methyl]-2-

pyrrolidinone and the product converted in 2 steps to title compound (3S,5S)-I which had EO50 of 0.06 μM against collagen-induced platelet aggregation in vitro.

IT 149354-09-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of cell aggregation inhibitors)

RN 149354-09-6 CAPLUS

CN 3H-3-Benzazepine-3-carboxylic acid, 1,2,4,5-tetrahydro-7-[[(2S,4R)-5-oxo-1-(3-phenylpropyl)-4-(2-propen-1-yl)-2-pyrrolidinyl]methoxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 149355-01-1P 149355-11-3P 149355-30-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as cell aggregation inhibitor)

RN 149355-01-1 CAPLUS

CN 3-Pyrrolidineacetic acid, 5-[[[3-(aminoiminomethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]oxy]methyl]-2-oxo-1-(3-phenylpropyl)-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149355-11-3 CAPLUS

CN 3-Pyrrolidineacetic acid, 2-oxo-1-(3-phenylpropyl)-5-[[(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]methyl]-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149355-30-6 CAPLUS
CN 3H-3-Benzazepine-3-carboxylic acid, 7-[[(2S,4S)-4-(carboxymethyl)-5-oxo-1-(3-phenylpropyl)-2-pyrrolidinyl]methoxy]-1,2,4,5-tetrahydro-, 3-(1,1-dimethylethyl) ester (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1981:47157 CAPLUS
DOCUMENT NUMBER: 94:47157
ORIGINAL REFERENCE NO.: 94:7689a,7692a
TITLE: Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines
INVENTOR(S): Shetty, Bola V.
PATENT ASSIGNEE(S): Pennwalt Corp., USA
SOURCE: U.S., 30 pp. Division of U.S. Ser. No. 747,151, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4210749	A	19800701	US 1979-41574	19790521
US 4233217	A	19801111	US 1979-41575	19790521

PRIORITY APPLN. INFO.: US 1968-711897 A1 19680311
US 1972-241091 A2 19720404
US 1974-523092 A1 19741112
US 1976-747151 A3 19761203
OTHER SOURCE(S): MARPAT 94:47157
GI



I



II

AB Benzazepines I (R = H, alkyl, alkenyl, aralkenyl, cycloalkylalkyl, aralkyl, heterocyclic alkyl; R1 = H, alkyl, Ph, phenylalkyl; R2 = H, alkyl; R3 = H, alkoxy, alkyl, halo, NO2, HO), useful as analgesics and narcotic antagonists, were prepared Thus, treatment of 3,4-(NCCH2)2C6H3OMe with HBr-AcOH followed by heating at 85° with NaOAc gave II, which was treated with BH3 to give I (R = R1 = R2 = H, R3 = MeO) (III). Refluxing III in 48% HBr gave I (R = R1 = R2 = H, R3 = HO).
IT 36134-31-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and acylation of)
RN 36134-31-3 CAPLUS
CN 3H-3-Benzazepine-3-ethanol, 1,2,4,5-tetrahydro-α-methyl-7-(phenylmethoxy)- (CA INDEX NAME)



IT 76209-91-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and hydrogenation of)
RN 76209-91-1 CAPLUS
CN 3H-3-Benzazepine-3-ethanol, 1,2,4,5-tetrahydro-α-methyl-7-(phenylmethoxy)-, acetate (ester) (9CI) (CA INDEX NAME)



IT 76210-14-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and pharmacol. of)
RN 76210-14-5 CAPLUS
CN 1H-3-Benzazepine, 7-(2-furanylmethoxy)-2,3,4,5-tetrahydro-, hydrochloride (9CI) (CA INDEX NAME)



L12 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1974:82731 CAPLUS
DOCUMENT NUMBER: 80:82731
ORIGINAL REFERENCE NO.: 80:13309a,13312a
TITLE: 1,2,4,5-Tetrahydro-3H,3-benzazepines
INVENTOR(S): Shetty, Bola V.
PATENT ASSIGNEE(S): Pennwalt Corp.
SOURCE: Fr. Demande, 73 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2171879	A1	19730928	FR 1972-4829	19720214
FR 2171879	B1	19750425		

PRIORITY APPLN. INFO.: FR 1972-4829 A 19720214
GI For diagram(s), see printed CA Issue.
AB Benzazepines I (R = CH2CH:CMe2, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, allyl, 2-(4-phenylpiperazino)-ethyl, CH2CMe:CH2, CH2C.tplbond.CH, Me, Et, Pr, CH2CH2Ph, CHMeCH2Ph, CH2CH2C6H4NH2-p, CH2CH2C6H4NHAc-p, CH2CH:CHPh, trans-2-phenylcyclopropylmethyl, CH2CH2OAc, CH2CHMeOAc, CHMeCH2C6H4NH2-p) were prepared by substitution of I (R = H). I (R = H, R1 = Me) was prepared by methylating 3,4-Me2C6H3OH, oxidizing the 3,4-Me2C6H3OMe, converting the 4-MeOC6H4(CO2H)2-1,2 to its anhydride, reducing to 4-MeOC6H4(CH2OH)2-1,2, and converting to 4-MeOC6H4(CH2Br)2-1,2 and 4-MeOC6H4(CH2CN)2-1,2, which was cyclized to 7-methoxy-1,2,4,5-tetrahydro-3H-3-benzazepine-2,4-dione and reduced with BH3. Demethylation with HBr gave I (R = R1 = H). I are analgesics and narcotic antagonists. Thus, I (R = CH2CH2C6H4NHAc-p, R1 = Me) had an oral ED50 in the writhing test of 32 mg/kg.
IT 36134-31-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 36134-31-3 CAPLUS
CN 3H-3-Benzazepine-3-ethanol, 1,2,4,5-tetrahydro-α-methyl-7-(phenylmethoxy)- (CA INDEX NAME)



L12 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1973:526338 CAPLUS
DOCUMENT NUMBER: 79:126338
ORIGINAL REFERENCE NO.: 79:20507a,20510a
TITLE: 1,2,4,5-Tetrahydro-3H-3-benzazepines
INVENTOR(S): Shetty, Bola V.
PATENT ASSIGNEE(S): Pennwalt Corp.
SOURCE: Ger. Offen., 82 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2207430	A1	19730823	DE 1972-2207430	19720214
DE 2207430	B2	19810723		
DE 2207430	C3	19820513		

PRIORITY APPLN. INFO.: DE 1972-2207430 A 19720214
GI For diagram(s), see printed CA Issue.
AB Benzazepines I (R = H, CH2CH:CMe2, CH2CMe:CH2, CH2CH:CHPh, allyl, CH2C.tplbond.CH, cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, trans-2-phenylcyclopropylmethyl, Me, Et, Pr, CH2CH2Ph, CHMeCH2Ph, CH2CH2C6H4NH2-p, CHMeCH2C6H4NH2-p, CH2CH2C6H4NHAc-p, CH2CH2OAc, (CH2)3OAc, 4-phenylpiperazinylethyl; R1 = H, Me) were prepared Thus, 3,4-Me2C6H3OH was methylated and oxidized to give 3,4-(HO2C)2C6H3OMe, whose anhydride was reduced to 3,4-(HOCH2)2C6H3OMe, brominated to 3,4-(BrCH2)2C6H3OMe, treated with NaCN to give 3,4-(NCCH2)2C6H3OMe, which was cyclized with HBr-HOAc to 7-methoxy-1,2,4,5-tetrahydro-3H-3-benzazepine-2,4-dione and reduced with B2H6 to I (R = H, R1 = Me) from which the other I were derived. I demonstrated antihistaminic, analgesic, anticholinergic, and morphine antagonist activity.
IT 36134-31-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 36134-31-3 CAPLUS
CN 3H-3-Benzazepine-3-ethanol, 1,2,4,5-tetrahydro-α-methyl-7-(phenylmethoxy)- (CA INDEX NAME)



L12 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1972:153628 CAPLUS
DOCUMENT NUMBER: 76:153628
ORIGINAL REFERENCE NO.: 76:25036h,25037a
TITLE: 1,2,4,5-Tetrahydro-3H-3-benzazepines as analgesics and antagonists of narcotics
PATENT ASSIGNEE(S): Wallace and Tiernan, Inc.
SOURCE: Brit., 42 pp.
CODEN: BRXXAA
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1268243		19720322	GB 1969-12844	19690311
CA 974989			CA	
US 3719669		19730306	US	19720327
PRIORITY APPLN. INFO.:			US 1968-711897	19680311

GI For diagram(s), see printed CA Issue.
AB H-3-Benzazepines (I, R was usually 7- or 8-MeO or 7-OH; R1 was, e.g., H, alkyl, cycloalkylmethyl, substituted phenethyl, p-MeC6H4SO2, a cetoxyalkyl; R2 = H3 Me), useful as analgesics, anticholinergics, antihistamines, and antagonists to narcotics, were prepared Thus, 50 g 4-methoxy-o-benzenediacetimide (II) was reduced by borane in THF at 10° to give 28 g I (R = 7-MeO, R1 = R2 = H), analyzed as the maleate. II was prepared from 3,4-dimethylphenol by methylation, oxidation to 4-methoxyphthalic acid, formation of the anhydride, reduction to 4-methoxy-o-xylene-α,α'-diol, dibromination of the diol, conversion to the dinitrile, and cyclization to the imide. Pharmacol. test results were given.
IT 36134-31-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 36134-31-3 CAPLUS
CN 3H-3-Benzazepine-3-ethanol, 1,2,4,5-tetrahydro-α-methyl-7-(phenylmethoxy)- (CA INDEX NAME)



L10 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2008 ACS on STN
RN 719989-00-1 REGISTRY
ED Entered STN: 30 Jul 2004
CN 1H-3-Benzazepine, 7-(2-furanylmethoxy)-2,3,4,5-tetrahydro- (CA INDEX NAME)
MF C15 H17 N O2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2008 ACS on STN
RN 791586-43-1 REGISTRY
ED Entered STN: 02 Dec 2004
CN 2,3-Pyridinedicarboxylic acid, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]- (CA INDEX NAME)
MF C21 H22 N2 O5
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L10 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2008 ACS on STN
RN 959867-51-7 REGISTRY
ED Entered STN: 02 Jan 2008
CN 1H-3-Benzazepine, 2,3,4,5-tetrahydro-7-[(3-methoxyphenyl)methoxy]-8-methyl-
(CA INDEX NAME)
MF C19 H23 N O2
CI COM
SR CA



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT